



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68, C12P 19/34, C12N 15/00, 15/85, 15/86, 15/11, C07H 21/04, A61K 48/00	A1	(11) International Publication Number: WO 98/28442 (43) International Publication Date: 2 July 1998 (02.07.98)
(21) International Application Number: PCT/US97/23619 (22) International Filing Date: 19 December 1997 (19.12.97) (30) Priority Data: 08/770,564 20 December 1996 (20.12.96) US 08/770,565 20 December 1996 (20.12.96) US (71) Applicant: GERON CORPORATION [US/US]; 230 Constitution Drive, Menlo Park, CA 94025 (US). (72) Inventors: KIM, Nam, Woo; 541 Winterberry Way, San Jose, CA 95129 (US). WU, Fred; 1143 Greene Terrace, Davis, CA 95616 (US). KEALEY, James, T.; 9 Mono Lane, San Anselmo, CA 94960 (US). PRUZAN, Ronald; 852 Matadero Avenue, Palo Alto, CA 94306 (US). WEINRICH, Scott, L.; 1830 Brewster Avenue, Redwood City, CA 94062 (US). (74) Agents: STORELLA, John, R. et al.; Two Embarcadero Center, Townsend and Townsend and Crew LLP, 8th floor, San Francisco, CA 94111 (US).		(81) Designated States: AU, CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: METHODS FOR DETECTING AND INHIBITING THE RNA COMPONENT OF TELOMERASE		
(57) Abstract Methods of detecting the RNA component of telomerase, diagnosing cancer, determining its prognosis, and inhibiting telomerase activity using polynucleotides that hybridize to the RNA component of mammalian telomerase.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHODS FOR DETECTING AND INHIBITING THE RNA COMPONENT OF TELOMERASE

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of the filing date of U.S. patent application 08/770, 564, filed December 20, 1996, and U.S. patent application 08/770,565, filed December 20, 1996.

FIELD OF THE INVENTION

The present invention provides methods for detecting and inhibiting the RNA component of telomerase in cell samples, using oligonucleotides directed to accessible regions of the RNA component of telomerase.

BACKGROUND OF THE INVENTION

Nearly all cells possess finite capacity to divide and replicate. One mechanism that regulates this finite life span involves telomeres, which are specialized structures found at the end of chromosomes. Telomeres are composed of protein and DNA that has the repeated sequence TTAGGG. Telomeres shorten each time that a cell divides, until they become critically short. This event is associated with the onset of cell senescence, after which the cell ceases to proliferate. In contrast, certain cells are "immortal" and have the capacity to divide indefinitely. Such cells include, for example, single-celled eukaryotic organisms, germline cells (i.e., oocytes and sperm), certain human cell cultures, and cancer cells. These cells do not exhibit telomere shortening upon cell division.

Most of these "immortal" cells, including about 90% of primary cancers, exhibit the activity of an enzyme, telomerase, whereas mortal cells exhibit very little or no telomerase activity. Telomerase is a ribonucleoprotein that regulates the length of telomeres. Telomerase acts as a DNA polymerase, adding telomeric repeat sequences to the chromosome ends using a sequence within the RNA component of telomerase as a

template. The RNA component of human telomerase, hTR, has been isolated (Feng *et al.*, *Science* 269: 1236-41 (1995) and United States Patent No. 5,583,016.

Due to the toll that cancer takes on human lives, there is a need to develop therapeutic methods for treatment of cancer. For example, inhibiting telomerase activity
5 in immortal cells, such as cancer cells, leads to telomere shortening and death. Feng *et al.*, *supra*, showed that transfecting an immortalized cell line with expression vectors that expressed hTR antisense transcripts resulted in telomere shortening and cell crisis, characterized by a marked inhibition of cell growth.

Furthermore, due to the importance of early diagnosis, there is a continued
10 need for additional methods of determining the diagnosis and prognosis of cancer, such as methods involving telomerase RNA detection. Monitoring changes in RNA expression, for example, hTR, requires reliable methods of identifying and quantitating the target molecule. Such changes in expression can be examined by specific amplification of small amounts of RNA. However, variation in the amplification
15 reaction may be magnified during subsequent amplification cycles, thus pointing to a need for internal controls. For example, 28S rRNA, which is separately reverse transcribed and then added to an amplification reaction, has been used as a co-amplification control (Khan *et al.*, *Neuroscience Letters* 147: 114-117 (1992)). Thus, there is a need to develop additional methods of reliably detecting the RNA component
20 of telomerase, particularly as it exists in its undenatured states in tissues, cells, and cell extracts.

SUMMARY OF THE INVENTION

Inhibitory polynucleotides directed against accessible regions of the RNA
25 component of telomerase (e.g., the RNA component of human telomerase ("hTR")) are useful for inhibiting telomerase activity in samples containing telomerase and in cells, including cultured cells or cells *in vivo*. Inhibitory polynucleotides include, for example, antisense, sense, ribozyme, and triple helix-forming polynucleotides. Inhibitory polynucleotides directed against sequences of the RNA component of telomerase can
30 inhibit the telomerase activity level in a cell by interfering with transcription of the RNA component, decreasing the half-life of the telomerase RNA component transcript, inhibiting assembly of the RNA component into the telomerase holoenzyme, or inhibiting the polymerase activity of telomerase. The inhibitory polynucleotides of the invention

specifically hybridize to a nucleotide sequence within the RNA component of telomerase, the primary RNA transcript, or a genomic sequence (either DNA strand) of the telomerase RNA component gene (e.g., the telomerase RNA gene promoter).

Furthermore, detection of the RNA component of telomerase is useful in
5 determining whether a cell is cancerous. The present invention thus describes methods of detecting the presence, absence, or amount of the RNA component of telomerase in a sample. The present invention also provides methods for diagnosis and prognosis of cancer. Polynucleotides that specifically hybridize to accessible regions of hTR in the telomerase ribonucleoprotein can be used to detect the presence or absence, and the
10 amount of hTR in a sample. In particular, a method of quantitation of a test polynucleotide such as hTR, using co-amplification of a test polynucleotide and a control polynucleotide, is useful for diagnosis and prognosis of cancer.

In one aspect, this invention provides a polynucleotide comprising an antisense sequence of at least 7 nucleotides that specifically hybridizes to a nucleotide
15 sequence within an accessible region of the RNA component of a mammalian telomerase, in particular, the RNA component of human telomerase. In one embodiment, the polynucleotide does not specifically hybridize to a nucleotide sequence within the template region of the RNA component of telomerase. In one embodiment of the polynucleotide, the antisense sequence is at most 50 nucleotides. The sequence of the
20 polynucleotide can consist essentially or exclusively of the antisense sequence. The antisense sequence can be complementary to the nucleotide sequence within an accessible region. In one embodiment, the accessible region is a sequence selected from nucleotides 137-196, 290-319, and 350-380 of hTR (see the hTR sequence, nucleotides 266-716 of the hTR gene shown in SEQ ID NO:1; see also Figure 1 (SEQ ID NO:29)).
25 In certain embodiments, the polynucleotide comprises DNA, RNA, or a nucleotide analog selected from phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs), and the like. In another embodiment, the polynucleotide of further comprises an inhibitory moiety. In another embodiment, the polynucleotide has a sequence
30 corresponding to SEQ ID NOS:2-14.

In another aspect, this invention provides an expression vector comprising a recombinant polynucleotide comprising expression control sequences operatively linked to a nucleotide sequence encoding polynucleotide comprising an antisense sequence of at

least 7 nucleotides that specifically hybridizes to a nucleotide sequence within an accessible region of the RNA component of telomerase, but that does not hybridize to a sequence within the template region of the telomerase RNA. The expression vector can be a viral vector or a plasmid vector comprising the recombinant polynucleotide.

5 In another aspect, this invention provides a method of inhibiting mammalian telomerase activity in a mammalian cell comprising the step of providing the cell with a polynucleotide comprising an antisense sequence of at least 7 nucleotides that specifically hybridizes to a nucleotide sequence within an accessible region of the RNA component of the telomerase but that does not hybridize to a sequence within the
10 template region of the telomerase RNA. In one embodiment the step of providing the polynucleotide comprises transfecting the cell with an expression vector comprising expression control sequences operatively linked to a nucleotide sequence encoding the polynucleotide which vector expresses the antisense polynucleotide. The polynucleotide inhibits the activity of the telomerase in cells expressing that enzyme. The cell can be a
15 cancer cell, a germ-line cell, a hematopoietic cell or a telomerase-expressing cell in culture.

 In another aspect, this invention provides pharmaceutical composition comprising a pharmaceutically acceptable carrier and (1) a a polynucleotide comprising an antisense sequence of at least 7 nucleotides that specifically hybridizes to a nucleotide
20 sequence within an accessible region of the RNA component of telomerase but that does not hybridize to a sequence within the template region of the telomerase RNA, or (2) an expression vector comprising expression control sequences operatively linked to a nucleotide sequence encoding the polynucleotide, which vector expresses the polynucleotide.

25 In another aspect, this invention provides a method of treating a telomerase-related condition involving cells exhibiting telomerase activity in a subject. The method comprises the step of administering to the subject an antisense polynucleotide in an amount effective to inhibit telomerase activity in the cells, wherein the polynucleotide comprises an antisense sequence of at least 7 nucleotides that
30 specifically hybridizes to a nucleotide sequence within an accessible region of the RNA component of the mammalian telomerase but that does not hybridize to a sequence within the template region of the telomerase RNA. Inhibiting telomerase activity in the cells provides the treatment of the condition. In one embodiment, the telomerase-related

condition is cancer and inhibition of telomerase activity in the cancer cells inhibits the growth of the cancer. In another embodiment, the polynucleotide comprises a pharmaceutical composition. In another embodiment the pharmaceutical composition is an injectable solution administered by injection. In another embodiment, the polynucleotide comprises an expression vector comprising expression control sequences operatively linked to a nucleotide sequence encoding the polynucleotide which vector expresses the polynucleotide.

In another aspect, this invention provides a ribozyme that cleaves the RNA component of a mammalian telomerase and, in particular, cleaves a nucleotide sequence within an accessible region of the RNA component of a mammalian telomerase. This invention also provides expression vectors comprising a recombinant polynucleotide comprising expression control sequences encoding the ribozyme. In another aspect, this invention provides methods of inhibiting telomerase activity in a cell by providing the cell with the ribozyme or with an expression vector comprising expression control sequences operatively linked to nucleotide sequences encoding the ribozyme. In one embodiment, the invention provides pharmaceutical compositions comprising the ribozyme or the expression vector. In another aspect, the invention provides a method of treating a telomerase-related condition, such as cancer or fertility, by administering to the subject the pharmaceutical composition.

In one aspect, this invention provides a method for detecting hTR in a sample, which is carried out in two steps: (1) first, a sample is contacted with a polynucleotide comprising a sequence of at least 7 nucleotides that specifically hybridizes to hTR within a region of hTR that is accessible in the telomerase ribonucleoprotein but that does not specifically hybridize to a template region of hTR; and (2) the specific hybridization is detected. Specific hybridization provides a detection of hTR in the sample.

In another embodiment, the sample can be a histological section of tissue and a sample that has been prepared for *in situ* detection.

In one embodiment, the polynucleotide includes a detectable moiety for determination of specific hybridization of the polynucleotide to hTR. The detectable moiety can be attached to the polynucleotide via a linker. The detectable moiety can be a fluorescent label, a radioactive label, an enzymatic label, a biotinyl group, or an epitope or oligonucleotide recognized by a secondary reporter, e.g., a probe.

In another embodiment, the polynucleotide is a primer that is used to initiation reverse transcription of hTR. Detection of hTR can be achieved by detection of an hTR reverse transcript, for example, by chain elongation of a sequence that is complementary to hTR with a nucleotide that includes a detectable moiety. The reverse transcript can also be detected by hybridization with a polynucleotide that is used as a probe and hybridizes to the reverse transcript. Detection of the reverse transcript can also be achieved by amplification of a sequence of hTR from the reverse transcript, for example, with a nucleotide that includes a detectable moiety. Detection of amplified hTR can also be achieved using a polynucleotide as a probe.

In another aspect, this invention provides a method of diagnosing cancer in a patient, which is composed of two steps: (1) determining a diagnostic value by detection of hTR in a patient sample, where detection of hTR uses the method of detection described herein; and (2) comparing the diagnostic value with a normal range of hTR in control cells, where a diagnostic value that is above normal range is diagnostic of cancer.

In another aspect, this invention provides a method of providing a prognosis for a cancer patient, which includes two steps: (1) determining the amount of hTR per cancer cell in a patient sample using the method of detecting hTR described herein and correlating the amount with an amount per cancer cell in the sample; and (2) comparing the amount of hTR per cancer cell with a prognostic value of hTR per cancer cell consistent with a particular prognosis for the cancer, where an amount of hTR per cell in a sample that is at the prognostic value provides the particular prognosis.

In one embodiment, the cancer is neuroblastoma, bladder, colon, breast, or prostate.

In another aspect, this invention provides a method of determining the amount of hTR in a sample, which includes five steps: (1) amplifying hTR; (2) amplifying a control polynucleotide; (3) determining an amount of amplified control and amplified hTR in the sample; (4) normalizing the amount of amplified hTR with respect to the amount of the amplified control polynucleotide to produce a normalized amount of hTR; and (5) comparing the normalized amount of hTR to a standard, thus providing a determination of the amount of hTR in a sample.

In one embodiment, the control polynucleotide is rRNA, preferably 28S rRNA.

In another embodiment, the efficiency of amplification of the control polynucleotide is different than the efficiency of amplification of the test polynucleotide in the sample, and in yet another embodiment the efficiency of amplification of the control polynucleotide is less than the efficiency of amplification of the test polynucleotide in the sample.

In another embodiment, before amplification, both the test and the control polynucleotides are reverse transcribed under conditions where reverse transcription of the control polynucleotide is less efficient than the test polynucleotide.

In another embodiment, the combined efficiency of chain elongation of the control polynucleotide and its complement is less than the combined efficiency of chain elongation of the test polynucleotide and its complement. In yet another embodiment, the combined efficiency of initiating chain elongation of the test and the control polynucleotides and their complements is similar to the difference in the amount of test and control polynucleotide in the sample.

In another embodiment, the combined efficiency of hybridization of the primer to the control polynucleotide and its complement is less than the combined efficiency of hybridization of the primer to the test polynucleotide and its complement.

In another embodiment, reduced efficiency of reverse transcription, amplification, hybridization, and chain elongation is achieved by including mismatches at the 5' end of the primer, and by providing a relatively shorter primer for the control polynucleotide.

In one embodiment, the step of amplifying a sequence of hTR comprises amplifying a sequence of hTR from an accessible region of hTR, wherein the region comprises nucleotide positions 137-196, 290-319, and 350-380 of hTR (see Figure 1 (SEQ ID NO:29) and the hTR sequence, nucleotides 266-716 of the hTR gene in SEQ ID NO:1). In yet another embodiment, the primers are selected from SEQ ID NOS:15-26.

BRIEF DESCRIPTION OF THE DRAWING

Fig. 1 presents the nucleotide sequence of the RNA component of human telomerase (SEQ ID NO:29) (nucleotides 266-716 of SEQ ID NO:1). The boxed areas, from nucleotides 137-196, 290-319 and 350-380, indicate regions of hTR accessible in the telomerase holoenzyme. Antisense molecules, indicated by numbers below the hTR sequence, have sequences complementary to the hTR sequence indicated by the arrows.

DETAILED DESCRIPTION

I. DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton *et al.*, *Dictionary of Microbiology and Molecular Biology* (2d ed. 1994); *The Cambridge Dictionary of Science and Technology* (Walker, ed., 1988); and Hale & Marham, *The Harper Collins Dictionary of Biology* (1991). Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are described. As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

"Polynucleotide" refers to a polymer composed of nucleotide units (ribonucleotides, deoxyribonucleotides, related naturally occurring structural variants, synthetic variants, and non-naturally occurring analogs thereof) linked via phosphodiester bonds, related naturally occurring structural variants, and synthetic non-naturally occurring analogs thereof. Thus, the term includes nucleotide polymers in which the nucleotides and the linkages between them include non-naturally occurring synthetic analogs, such as, for example and without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs), and the like. Such polynucleotides can be synthesized, for example, using an automated DNA synthesizer. The term "nucleic acid" typically refers to large polynucleotides. The term "oligonucleotide" typically refers to short polynucleotides, generally no greater than about 50 nucleotides. It will be understood that when a nucleotide sequence is represented by a DNA sequence (i.e., A, T, G, C), this also includes an RNA sequence (i.e., A, U, G, C) in which "U" replaces "T."

Conventional notation is used herein to describe polynucleotide sequences: the left-hand end of a single-stranded polynucleotide sequence is the 5'-end; the left-hand direction of a double-stranded polynucleotide sequence is referred to as the 5'-direction. The direction of 5' to 3' addition of nucleotides to nascent RNA transcripts is referred to as the transcription direction. The DNA strand having the same sequence as an mRNA is referred to as the "coding strand"; sequences on the DNA strand having the same

sequence as an mRNA transcribed from that DNA and which are located 5' to the 5'-end of the RNA transcript are referred to as "upstream sequences"; sequences on the DNA strand having the same sequence as the RNA and which are 3' to the 3' end of the coding RNA transcript are referred to as "downstream sequences."

5 "Polypeptide" refers to a polymer composed of amino acid residues, related naturally occurring structural variants, synthetic variants, and non-naturally occurring analogs thereof linked via peptide bonds, related naturally occurring structural variants, and synthetic non-naturally occurring analogs thereof. Synthetic polypeptides can be synthesized, for example, using an automated polypeptide synthesizer. The term
10 "protein" typically refers to large polypeptides. The term "peptide" typically refers to short polypeptides.

Conventional notation is used herein to portray polypeptide sequences: the left-hand end of polypeptide sequences is the amino-terminus; the right-hand end of polypeptide sequences is the carboxyl-terminus.

15 Terms used to describe sequence relationships between two or more nucleotide sequences or amino acid sequences include "reference sequence," "selected from," "comparison window," "identical," "percentage of sequence identity," "substantially identical," "complementary," and "substantially complementary."

A "reference sequence" is a defined sequence used as a basis for a
20 sequence comparison and may be a subset of a larger sequence, e.g., a complete cDNA, protein, or gene sequence.

Because two polynucleotides or polypeptides each may comprise (1) a sequence (i.e., only a portion of the complete polynucleotide or polypeptide sequence) that is similar between the two polynucleotides, or (2) a sequence that is divergent
25 between the two polynucleotides, sequence comparisons between two (or more) polynucleotides or polypeptides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity.

A "comparison window" refers to a conceptual segment of typically at
30 least 12 consecutive nucleotide or 4 consecutive amino acid residues that is compared to a reference sequence. The comparison window frequently is at least 15 or at least 25 nucleotides in length or at least 5 or at least 8 amino acids in length. The comparison window may comprise additions or deletions (i.e., gaps) of about 20 percent or less as

compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by computerized implementations of algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package
5 Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, WI) or by inspection, and the best alignment (i.e., resulting in the highest percentage of homology over the comparison window) generated by any of the various methods is selected.

A subject nucleotide sequence or amino acid sequence is "identical" to a reference sequence if the two sequences are the same when aligned for maximum
10 correspondence over the length of the nucleotide or amino acid sequence.

The "percentage of sequence identity" between two sequences is calculated by comparing two optimally aligned sequences over a comparison window, determining the number of positions at which the identical nucleotide or amino acid occurs in both sequences to yield the number of matched positions, dividing the number of matched
15 positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity.

When percentage of sequence identity is used in reference to polypeptides it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions, where amino acids residues are substituted for other amino acid
20 residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore are not likely to change the functional properties of the molecule. Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a
25 conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., according to known algorithm (*see, e.g., Meyers &*
30 *Miller, Computer Applic. Biol. Sci.*, 4: 11-17 (1988); *Smith & Waterman, Adv. Appl. Math.* 2: 482 (1981); *Needleman & Wunsch, J. Mol. Biol.* 48: 443 (1970); *Pearson & Lipman, Proc. Natl. Acad. Sci. USA* 85: 2444 (1988); *Higgins & Sharp, Gene* 73: 237-244 (1988); *Higgins & Sharp, CABIOS* 5: 151-153 (1989); *Corpet et al., Nucleic*

Acids Research 16: 10881-90 (1988); Huang *et al.*, *Computer Applications in the Biosciences* 8: 155-65 (1992); and Pearson *et al.*, *Methods in Molecular Biology* 24: 307-31 (1994). Alignment is also often performed by inspection and manual alignment.

A subject nucleotide sequence or amino acid sequence is "substantially identical" to a reference sequence if the subject amino acid sequence or nucleotide sequence has at least 80% sequence identity over a comparison window. Thus, sequences that have at least 85% sequence identity, at least 90% sequence identity, at least 95% sequence identity or at least 99% sequence identity with the reference sequence are also substantially identical. Two sequences that are identical to each other are, of course, also substantially identical.

"Complementary" refers to the topological compatibility or matching together of interacting surfaces of two polynucleotides. Thus, the two molecules can be described as complementary, and furthermore, the contact surface characteristics are complementary to each other. A first polynucleotide is complementary to a second polynucleotide if the nucleotides of the first polynucleotide have the sequence of the nucleotides in the polynucleotide binding partner of the second polynucleotide. Thus, the polynucleotide whose sequence 5'-TATAC-3' is complementary to a polynucleotide whose sequence is 5'-GTATA-3'.

A nucleotide sequence is "substantially complementary" to a reference nucleotide sequence if the sequence complementary to the subject nucleotide sequence is substantially identical to the reference nucleotide sequence.

"Encoding" refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA, mRNA and other RNA molecules such as hTR) or a defined sequence of amino acids and the biological properties resulting therefrom. Thus, a gene encodes a protein if transcription and translation of mRNA produced by that gene produces the protein in a cell or other biological system. Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and non-coding strand, used as the template for transcription, of a gene or cDNA can be referred to as encoding the protein or other product of that gene or cDNA. Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide

sequences that are degenerate versions of each other and that encode the same amino acid sequence. Nucleotide sequences that encode proteins and RNA may include introns.

"Expression control sequence" refers to a nucleotide sequence in a polynucleotide that regulates the expression (transcription and/or translation) of a nucleotide sequence operatively linked thereto. "Operatively linked" refers to a functional relationship between two parts in which the activity of one part (e.g., the ability to regulate transcription) results in an action on the other part (e.g., transcription of the sequence). Expression control sequences can include, for example and without limitation, sequences of promoters (e.g., inducible or constitutive), enhancers, transcription terminators, a start codon (i.e., ATG), splicing signals for introns, and stop codons.

"Expression vector" refers to a vector comprising a recombinant polynucleotide comprising expression control sequences operatively linked to a nucleotide sequence to be expressed. An expression vector comprises sufficient *cis*-acting elements for expression; other elements for expression can be supplied by the host cell or *in vitro* expression system. Expression vectors include all those known in the art, such as cosmids, plasmids (e.g., naked or contained in liposomes) and viruses that incorporate the recombinant polynucleotide.

"Recombinant" refers to polynucleotides synthesized or otherwise manipulated *in vitro* ("recombinant polynucleotides") and to methods of using recombinant polynucleotides to produce gene products encoded by those polynucleotides in cells or other biological systems. For example, an amplified or assembled product polynucleotide may be inserted into a suitable DNA vector, such as a bacterial plasmid, and the plasmid can be used to transform a suitable host cell. A host cell that comprises the recombinant polynucleotide is referred to as a "recombinant host cell". The gene is then expressed in the recombinant host cell to produce, e.g., a "recombinant protein." A recombinant polynucleotide may serve a non-coding function (e.g., promoter, origin of replication, ribosome-binding site, etc.) as well.

"Pharmaceutical composition" refers to a composition suitable for pharmaceutical use in a mammal. A pharmaceutical composition comprises a pharmacologically effective amount of an active agent and a pharmaceutically acceptable carrier. "Pharmacologically effective amount" refers to that amount of an agent effective to produce the intended pharmacological result. "Pharmaceutically acceptable carrier"

refers to any of the standard pharmaceutical carriers, buffers, and excipients, such as a phosphate buffered saline solution, 5% aqueous solution of dextrose, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents and/or adjuvants. Suitable pharmaceutical carriers and formulations are described in

5 *Remington's Pharmaceutical Sciences* (19th ed., 1995). Preferred pharmaceutical carriers depend upon the intended mode of administration of the active agent. Typical modes of administration include enteral (e.g., oral) or parenteral (e.g., subcutaneous, intramuscular, or intravenous intraperitoneal injection; or topical, transdermal, or transmucosal administration).

10 "Specifically binds to" refers to the ability of one molecule, typically a molecule such as an antibody or polynucleotide, to contact and associate with another specific molecule even in the presence of many other diverse molecules. For example, a single-stranded polynucleotide can "specifically bind to" a single-stranded polynucleotide that is complementary in sequence, and an antibody "specifically binds to" or "is

15 specifically immunoreactive with" its corresponding antigen. Thus, under designated immunoassay conditions, an antibody binds preferentially to a particular protein and not in a significant amount to other proteins present in the sample. Specific binding to a protein under such conditions requires an antibody selected for its specificity for a particular protein. To select antibodies specifically immunoreactive with a particular

20 protein, one can employ a variety of means, i.e., solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein (see Harlow & Lane, *Antibodies, A Laboratory Manual* (1988)).

A polynucleotide "specifically hybridizes" to a target polynucleotide if the polynucleotide hybridizes to the target under stringent conditions. "Stringent conditions"

25 refers to temperature and ionic conditions used in nucleic acid hybridization. Stringent conditions depend upon the various components present during hybridization. Generally, stringent conditions are selected to be about 10°C, and preferably about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of a

30 target sequence hybridizes to a complementary polynucleotide.

A first sequence is an "antisense sequence" with respect to a second sequence if a polynucleotide whose sequence is the first sequence specifically hybridizes with a polynucleotide whose sequence is the second sequence.

"Substantially pure" means an object species is the predominant species present (i.e., on a molar basis, more abundant than any other individual macromolecular species in the composition), and a substantially purified fraction is a composition wherein the object species comprises at least about 50% (on a molar basis) of all macromolecular species present. Generally, a substantially pure composition means that about 80 to 90% or more of the macromolecular species present in the composition is the purified species of interest. The object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) if the composition consists essentially of a single macromolecular species. Solvent species, small molecules (<500 Daltons), stabilizers (e.g., BSA), and elemental ion species are not considered macromolecular species for purposes of this definition.

"Suitable reaction conditions" are those conditions suitable for conducting a specified reaction using commercially available reagents. Such conditions are known or readily established by those of skill in the art for a variety of reactions. For example, suitable polymerase chain reaction (PCR) conditions include those conditions specified in U.S. Patents 4,683,202; 4,683,195; 4,800,159; and 4,965,188. As one example and not to limit the invention, suitable reaction conditions can comprise: 0.2 mM each dNTP, 2.2 mM MgCl₂, 50 mM KCl, 10 mM Tris-HCl, pH 9.0, and 0.1% Triton X-100.

"Telomerase" or "telomerase ribonucleoprotein" refers to a ribonucleoprotein enzyme of eukaryotic origin identifiable by its ability to polymerize a DNA sequence of a eukaryotic telomere. Telomerase is further characterized by an RNA component having sequences complementary to at least part of the telomeric repeat of the source species and by one or more protein components. As used herein, "mammalian telomerase" and "human telomerase" refer to telomerases that can be found naturally in various mammalian or human cells, respectively, or having polypeptide components with the same amino acid sequences, and RNA components with the same nucleotide sequences. Human telomerase contains the RNA component, "hTR." The term "telomerase" includes all allelic forms of telomerase, including wild-type and mutant forms.

"Telomerase activity" refers to the synthesis of telomeric DNA by telomerase. A preferred assay method for detecting telomerase activity is the TRAP assay (see International Application published under the PCT, WO 95/13381; see also the commercially available TRAP-eze™ telomerase assay kit (Oncor); Feng *et al.*, *supra*). A

second type of assay is the "conventional" telomerase assay. This assay measures the amount of radioactive nucleotides incorporated into elongation products, polynucleotides, formed by nucleotide addition to a telomerase substrate or primer. The radioactivity incorporated can be measured as a function of the intensity of a band on a

5 PhosphorImager™ screen exposed to a gel on which the radioactive products are separated. A test experiment and a control experiment can be compared by visually using the PhosphorImager™ screens (*see* Morin, *Cell* 59: 521-529 (1989)).

"Telomerase-related condition" refers to a condition in a subject maintained by telomerase activity within cells of the individual. Telomerase-related
10 conditions include, e.g., cancer (telomerase-activity in malignant cells), fertility (telomerase activity in germ-line cells) and hematopoiesis (telomerase activity in hematopoietic stem cells).

"Accessible region of the RNA component of telomerase" refers to a region of an RNA component of telomerase (e.g., hTR) to which an antisense
15 polynucleotide can specifically hybridize when the RNA component is part of the telomerase ribonucleoprotein.

The "template region" of the RNA component of mammalian telomerase refers to a subsequence of the RNA component of mammalian telomerase that serves as a template for synthesis of telomeric repeats. All vertebrates appear to have the conserved
20 sequence 5'-TTAGGG-3' at chromosome ends, although subtelomeric sequences can vary (*see, e.g.,* Harley & Villeponteau, *Current Opin. in Gen. and Dev.* 5: 249-255 (1995)). The template region is complementary to at least the single telomeric repeat sequence, and can also include a second portion of the telomeric repeat sequence. For example, the template region of hTR is 5'-CTAACCCTAA-3' (SEQ ID NO:28), located at
25 nucleotides 46-55 of hTR (311-320 on SEQ ID NO:1).

"Primer" refers to a polynucleotide that is capable of specifically hybridizing to a complementary polynucleotide template and providing a point of initiation for synthesis of a complementary polynucleotide. Such synthesis occurs when the polynucleotide primer is placed under conditions in which synthesis is induced, i.e.,
30 in the presence of nucleotides, a complementary polynucleotide template, and an agent for polymerization such as DNA polymerase. A primer is typically single-stranded, but may be double-stranded. Primers are typically deoxyribonucleic acids, but a wide variety of synthetic and naturally occurring primers are useful for many applications. A

primer is complementary to the template to which it is designed to hybridize to serve as a site for the initiation of synthesis, but need not reflect the exact sequence of the template. In such a case, specific hybridization of the primer to the template depends on the stringency of the hybridization conditions. Primers can be labeled with, e.g.,
5 chromogenic, radioactive, or fluorescent moieties and used as detectable moieties.

"Probe" refers to a polynucleotide that is capable of specifically hybridizing to a complementary sequence of another polynucleotide. A probe specifically hybridizes to a target complementary polynucleotide, but need not reflect the exact complementary sequence of the template. In such a case, specific hybridization of the
10 probe to the target depends on the stringency of the hybridization conditions. Probes can be labeled with, e.g., chromogenic, radioactive, or fluorescent moieties and used as detectable moieties.

"Detectable moiety" or a "label" refers to a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For
15 example, useful labels include ^{32}P , ^{35}S , fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, peroxidase, alkaline phosphatase, digoxigenin, haptens and proteins for which antisera or monoclonal antibodies are available, or nucleic acid molecules with a sequence complementary to a secondary probe. The detectable moiety often generates a measurable signal, such as
20 radioactivity, that can be used to quantitate the amount of bound detectable moiety. The detectable moiety can be incorporated in or attached to a primer or probe either covalently, or through ionic, van der Waals or hydrogen bonds, e.g., incorporation of radioactive nucleotides, or biotinylated nucleotides that are recognized by streptavidin. The detectable moiety may be directly or indirectly detectable. Indirect detection can
25 involve the binding of a second directly or indirectly detectable moiety to the detectable moiety. For example, the detectable moiety can be the ligand of a binding partner, such as biotin, which is a binding partner for streptavidin, or a nucleotide sequence, which is the binding partner for a complementary sequence, to which it can specifically hybridize. The binding partner may itself be directly detectable, for example, an antibody may be
30 itself labeled with a fluorescent molecule. The binding partner also may be indirectly detectable, for example, a nucleic acid having a complementary nucleotide sequence can be a part of a branched DNA molecule that is in turn detectable through hybridization with other labeled nucleic acid molecules.

"Linker" refers to a molecule that joins two other molecules, either covalently, or through ionic, van der Waals or hydrogen bonds, e.g., a nucleic acid molecule that hybridizes to one complementary sequence at the 5' end and to another complementary sequence at the 3' end, thus joining two non-complementary sequences.

5 "Amplification" refers to any means by which a polynucleotide sequence is copied and thus expanded into a larger number of polynucleotide molecules, e.g., by reverse transcription, polymerase chain reaction, and ligase chain reaction.

"Prognostic value" refers to an amount (e.g., the presence or absence and/or the level) of the RNA component of telomerase detected in a given cancerous cell
10 type that is consistent with a particular prognosis for the cancer. The amount (including a zero amount) of RNA component of telomerase detected in a sample is compared to the prognostic value for the cell such that the relative comparison of the values indicates the likely outcome of the cancer's progression. Typically the prognostic value is also compared to the amount of the RNA component of telomerase present in a control
15 normal cell, e.g., an adjacent cell of the same tissue type from the same patient. RNA component of telomerase prognostic values can also be compared with additional prognostic markers, or evaluated in conjunction with such markers, e.g., telomerase activity and other non-telomerase related prognostic markers, e.g., DNA ploidy and tumor specific cell surface markers.

20 "Diagnostic value" refers to a value that is determined for the amount (e.g., the presence or absence and/or the level) of RNA component of telomerase detected in a sample, which is then compared to a normal range of the RNA component of telomerase in a cell such that the relative comparison of the values provides a reference value for diagnosing cancer. Depending upon the method of detection, the
25 diagnostic value may be a determination of the level of the RNA component of telomerase in a sample, or a determination of the presence or absence of the RNA component of telomerase in a sample. The diagnostic value may also be a relative value, such as a plus or a minus score, and includes a value indicating the absence of the RNA component of telomerase in a sample. Typically the diagnostic value is compared to the
30 amount of the RNA component of telomerase present in a control normal cell, e.g., an adjacent cell of the same tissue type from the same patient. RNA component of telomerase diagnostic values can also be compared with additional diagnostic markers, or evaluated in conjunction with such markers, e.g., telomerase activity and other non-

telomerase related diagnostic markers, e.g., DNA ploidy and tumor specific cell surface markers.

II. THE RNA COMPONENT OF TELOMERASE

Mammalian telomerase is a ribonucleoprotein complex that includes an RNA component. The RNA component of telomerase from humans and mice has been isolated and sequenced (*see, e.g., Feng et al., Science* 269: 1236-41 (1995); United States Patent No. 5,583,016; and Blasco *et al., Science* 269: 1267-1270 (1995)). Human genomic DNA encoding hTR has been cloned, sequenced and placed on deposit. A lambda clone designated "28-1" contains an ~15 kb insert containing human telomerase RNA component gene sequences. Clone 28-1 was deposited with the American Type Culture Collection pursuant to the Budapest Treaty and granted accession number ATCC 75925. Plasmid pGRN33 contains an ~2.5 kb HindIII-SacI insert containing sequences from lambda clone 28-1 that contain the sequence of hTR. Plasmid pGRN33 was deposited with the American Type Culture Collection pursuant to the Budapest Treaty and granted accession number ATCC 75926. A PstI fragment of the ~2.4 kb SauIIA1-HindIII fragment of clone 28-1 also contains the hTR sequence. The sequence of the PstI fragment is provided in SEQ ID NO:1, below. The nucleotides of hTR are indicated by stars (nucleotides 266-716). The template region is underlined.

```
1  CTGCAGAGGATAGAAAAAGGCCCTCTGATACCTCAAGTTAGTTTCACCTTTAAAGAAGG
   GACGTCTCTCTATCTTTTTTCCGGGAGACTATGGAGTTCAATCAAAGTGGAATTTCTTCC
   ^
   PST1
61  TCGGAAGTAAAGACGCAAAGCCTTTCCCGGACGTGCGGAAGGGCAACGTCCTTCCTCATG
   AGCCTTCATTTCTGCGTTTCGGAAAGGGCTGCACGCCTTCCCGTTGCAGGAAGGAGTAC
121 GCCGAAATGGAACCTTTAATTTCCCGTTCCCCCAACCAGCCCGCCGAGAGAGTGACTC
   CGGCCTTTACCTTGAAATTAAAGGGCAAGGGGGTTGGTCGGGCGGGCTCTCTCACTGAG
181 TCACGAGAGCCGCGAGAGTCAGCTTGGCCAATCCGTGCGGTGCGGCGGCGCTCCCTTTAT
   AGTGCTCTCGGCGCTCTCAGTCGAACCGTTAGGCACGCCAGCCGCGCGGAGGGAAATA
35
   *****
241 AAGCCGACTCGCCCGGCAGCGCACCGGGTTGCGGAGGGTGGGCCTGGGAGGGGTGGTGGC
   TTCGGCTGAGCGGGCCGTGCGGTGGCCCAACGCCTCCACCCGACCCCTCCCCACCACCG
40
   *****
301 CATTTTTTGTCTAACCCTAACTGAGAAGGGCGTAGGCGCCGTGCTTTTGCTCCCCGCGCG
   GTAAAAAACAGATTGGGATTGACTCTTCCCGCATCCGCGGCACGAAAACGAGGGGCGCGC
45
   *****
361 CTGTTTTTCTCGCTGACTTTTCAGCGGGCGGAAAAGCCTCGGCCTGCCGCCTTCCACCGTT
   GACAAAAAGAGCGACTGAAAGTCGCCCGCCTTTTCGGAGCCGGACGGCGGAAGGTGGCAA
```



```

*****
421 CATTCTAGAGCAAACAAAAATGTCAGCTGCTGGCCCGTTGCCCCCTCCCGGGGACCTGC
5   GTAAGATCTCGTTTGT TTTTACAGTCGACGACCGGGCAAGCGGGGAGGGCCCCTGGACG

*****
481 GGCGGGTTCGCCTGCCCAGCCCCGAACCCCGCCTGGAGGCCGCGGTGCGCCCGGGGCTTC
10  CCGCCCAGCGGACGGGTGCGGGGGCTTGGGGCGGACCTCCGGCGCCAGCCGGGCCCCGAAG

*****
541 TCCGGAGGCACCCACTGCCACCGCGAAGAGTTGGGCTCTGTCAGCCGCGGGTCTCTCGGG
15  AGGCCTCCGTGGGTGACGGTGGCGCTTCTCAACCCGAGACAGTCGGCGCCAGAGAGCCC

*****
601 GGCGAGGGCGAGGTTTCAGGCCTTTCAGGCCGCGAGGAAGAGGAACGGAGCGAGTCCCCGCG
20  CCGCTCCCGCTCCAAGTCCGGAAGTCCGGCGTCTTCTCCTTGCCCTCGCTCAGGGGCGC

*****
661 CGCGGCGCGATTCCCTGAGCTGTGGGACGTGCACCCAGGACTCGGCTCACACATGCAGTT
25  GCGCCGCGCTAAGGGACTCGACACCCTGCACGTGGGTCTTGAGCCGAGTGTGTACGTCAA

721 CGCTTTCCTGTTGGTGGGGGGAACGCCGATCGTGCGCATCCGTACCCCTCGCCGGCAGT
    GCGAAAGGACAACCACCCCTTTCGCGCTAGCACGCGTAGGCAGTGGGGAGCGGCCGTCA

781 GGGGGCTTGTGAACCCCCAAACCTGACTGACTGGGCCAGTGTGCTGCAAATTGGCAGGAG
30  CCCCCGAACACTTGGGGGTTTGGACTGACTGACCCGGTCACACGACGTTTAACCGTCCTC

841 ACGTGAAGGCACCTCCAAAGTCGGCCAAAATGAATGGGCAGTGAGCCGGGGTTGCCTGGA
    TGACTTCCGTGGAGGTTTCAGCCGGT TTTACTTACCCGTCACTCGGCCCAACGGACCT

35  901 GCCGTTTCCTGCGTGGGTTCTCCCGTCTTCCGCTTTTTTGTGCTTTTATGGTTGTATTAC
    CGGCAAGGACGCACCCAAGAGGGCAGAAGGCGAAAAACAACGGAAAATACCAACATAATG

961 AACTTAGTTCTCTGCTCTGCAG
    TTGAATCAAGGACGAGACGTC
    ^
    976
    PST1 (SEQ ID NO:1)
40

```

III. ACCESSIBLE REGIONS OF THE RNA COMPONENT OF TELOMERASE

Regions of the RNA component of telomerase, e.g., hTR, that are accessible in the native telomerase ribonucleoprotein have been identified. Such accessible regions are useful for detecting the presence, absence, amount of hTR, and for inhibiting telomerase activity. The regions can be identified with two approaches. The first approach involves contacting samples containing human telomerase with a variety of polynucleotides having sequences complementary to the sequence of hTR under hybridization conditions, contacting the telomerase with RNase H, which cleaves the RNA strand of an RNA-DNA duplex, and determining whether hTR had been cleaved. Antisense oligonucleotides that supported hTR cleavage were complementary to nucleotides 137-196, 290-319 and 350-380 of hTR (*see, e.g.*, sequences listed in Table II and Figure 1). Specific polynucleotides capable of supporting RNase H cleavage are

described in more detail in Example 2. The second approach is oligo-decoration. This method indicated that nucleotides 167-196 are accessible. Regions of hTR accessible in the telomerase ribonucleoprotein comprise these areas. Other accessible areas of hTR can be identified by similar assays using antisense polynucleotides whose sequences are substantially complementary to a nucleotide sequence selected from hTR. The RNA component of telomerase of other mammals also contains accessible regions in the telomerase ribonucleoprotein. Accessible regions of the RNA component of telomerase and their uses are also described in United States patent application 08/770,564, filed December 20, 1996 and in United States patent application 08/777,565, filed December 20, 1996.

IV. POLYNUCLEOTIDE PROBES AND PRIMERS

The methods of the invention involve the use of polynucleotides that specifically hybridize to sequences of the RNA component of telomerase in a sample. The polynucleotide probes and primers used in the invention have the ability to specifically hybridize to a subsequence of the RNA component of telomerase or its complement under the conditions used in the particular method of detection or inhibition. Probes or primers that can specifically hybridize to, for example, the sequence of hTR described above, are used in the invention. One embodiment of oligonucleotides that can hybridize to hTR is described in Example 1 (SEQ ID NO:25 and SEQ ID NO:26). Polynucleotide primers and probes that specifically hybridize to the RNA component of mammalian telomerase are also described in U.S. Patent No. 5,583,016; U.S. Patent Application Nos: 08/272,102, filed July 7, 1994; 08/472,802, filed June 7, 1995; 08/482,115, filed June 7, 1995; 08/521,634, filed August 31, 1995; 08/630,019, filed April 9, 1996; 08/660,678, filed June 5, 1996; and International Application PCT/US95/08530, filed July 6, 1995.

Any suitable region of the RNA component of telomerase may be chosen as a target for polynucleotide hybridization. A detectable moiety bound to either an oligonucleotide primer or a probe is subsequently used to detect hybridization of an oligonucleotide primer to the RNA component. Detection of labeled material bound to the RNA component of telomerase in a sample provides a means of determining a diagnostic or prognostic value (see Section XI, below). The methods of the invention are also useful in detecting the presence, absence or level of hTR in tissue biopsies and

histological sections where the detection method is carried out *in situ*, typically after amplification of hTR using a primer set. Inhibition of telomerase using polynucleotides that bind to hTR or its gene also provide therapeutic approaches for telomerase-related diseases such as cancer. Such polynucleotides can include additional inhibitory or detectable moieties.

The conditions required for specific hybridization of polynucleotide probes and primers vary according to the sequence and length of the primer or probe, and the reaction conditions of the hybridization reaction. Determination of the conditions for specific hybridization are known by those skilled in the art (*see* Sambrook *et al.*, *Molecular Cloning -- A Laboratory Manual* (2nd ed. 1989); Ausubel *et al.*, *Current Protocols in Molecular Biology*). In one embodiment, the conditions for hybridization are those described in Examples 1 and 2. Nucleotide substitutions, deletions, and additions may be incorporated into the polynucleotides used in the invention, as long as the characteristic ability to specifically hybridize to the target hTR sequence or its complement is retained. Nucleotide sequence variation may result from sequence polymorphisms of various alleles, minor sequencing errors, and the like.

Although primers and probes can differ in sequence and length, the primary differentiating factor is one of function: primers serve as an initiation point for DNA synthesis of a target nucleic acid, as in RT and PCR reactions, while probes are typically used for hybridization to and detection of a target nucleic acid. Typical lengths of primers or probes can range from 7 to 50 or more nucleotides. A primer or probe can also be labeled with a detectable moiety for detection of hybridization of the primer or probe to the target hTR nucleic acid.

As a general point regarding the nucleic acids used in the invention, those of skill in the art recognize that the nucleic acids used in the invention include both DNA and RNA molecules and naturally occurring modifications thereof, as well as synthetic, non-naturally occurring analogs of the same, and heteropolymers, of deoxyribonucleotides, ribonucleotides, and/or synthetic analogues of either. The particular composition of a nucleic acid or nucleic acid analog will depend upon the purpose for which the material will be used and the environment in which the material will be placed. Modified or synthetic, non-naturally occurring nucleotides have been designed to serve a variety of purposes and to remain stable in a variety of environments, such as those in which nucleases are present, as is well known in the art. Modified or

synthetic non-naturally occurring nucleotides, as compared to naturally occurring ribo- or deoxyribonucleotides may differ with respect to the carbohydrate (sugar), phosphate bond, or base portions of the nucleotide, or may even contain a non-nucleotide base (or no base at all) in some cases (*see, e.g.,* Arnold *et al.*, PCT patent publication no. WO 89/02439). For example, the modified or non-naturally occurring nucleic acids of the invention can include biotinylated nucleic acids, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides and peptide-nucleic acids (*see, e.g.,* U.S. Patent Nos: 5,506,212, 5,521,302, 5,541,307, and 5,510,476).

10 The polynucleotides of the invention can also be chemically modified, e.g., so as to improve stability in the body. Properties of the polynucleotide can be engineered to impart stability (e.g., nuclease resistance), tighter binding or the desired T_m . For example, the polynucleotide can include modified nucleotide analogs, such as those already described. The polynucleotide can comprise mixtures of naturally
15 occurring nucleotides and nucleotide analogues. Techniques for rendering polynucleotides nuclease-resistant include those described in International patent publication No. 94/12633. A general approach to constructing various polynucleotides useful in inhibitory polynucleotide therapy is reviewed by Vander Krol *et al.*, *Biotechniques* 6: 958-976 (1988); and by Stein *et al.*, *Cancer Res.* 48: 2659-2668 (1988)
20 (*see also Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression*, pp. 79-196 (Cohen, ed., 1989); and *Antisense RNA and DNA* (Melton, ed., 1988)).

 In certain embodiments inhibitory polynucleotides comprise a derivatized substituent which is substantially non-interfering with respect to hybridization of the inhibitory polynucleotide to the target polynucleotide. Typically such inhibitory
25 polynucleotides are derivatized, and additional chemical substituents are attached, either during or after polynucleotide synthesis, respectively, and are thus localized to a complementary sequence in the target polynucleotide where they produce an alteration or chemical modification to a local DNA sequence and/or to a protein component.

 Preferred attached chemical substituents include: europium (III) texaphyrin, cross-linking agents, psoralen, metal chelates (e.g., iron/EDTA chelate for iron catalyzed cleavage), topoisomerases, endonucleases, exonucleases, ligases, phosphodiesterases, photodynamic porphyrins, chemotherapeutic drugs (e.g., adriamycin, doxorubicin), intercalating agents, base-modification agents, immunoglobulin chains, and

oligonucleotides. Iron/EDTA chelates are particularly preferred chemical substituents where local cleavage of a polynucleotide sequence is desired (Hertzberg *et al.*, *J. Am. Chem. Soc.* 104: 313 (1982); Hertzberg & Dervan, *Biochemistry* 23: 3934 (1984); Taylor *et al.*, *Tetrahedron* 40: 457 (1984); and Dervan, *Science* 232: 464 (1986)).

5 Preferred attachment chemistries include: direct linkage, e.g., via an appended reactive amino group (Corey & Schultz, *Science* 238: 1401 (1988)) and other direct linkage chemistries, although streptavidin/biotin and digoxigenin/anti-digoxigenin antibody linkage methods may also be used. Methods for linking chemical substituents are provided in U.S. Patents 5,135,720, 5,093,245, and 5,055,556. Other linkage
10 chemistries may be used at the discretion of the practitioner.

Polynucleotides which correspond to all or a substantial portion of a mammalian telomerase RNA component (i.e., "sense" polynucleotides) may also be derivatized and used to react with telomeric repeat sequences in the genome and produce adducts or other modification of the chemical environment at telomere regions of the
15 chromosomes.

Oligonucleotides preferably are synthesized on an Applied BioSystems or other commercially available oligonucleotide synthesizer according to specifications provided by the manufacturer. Oligonucleotides may be prepared using any suitable method, such as the phosphotriester and phosphodiester methods, or automated
20 embodiments thereof. In one such automated embodiment, diethylphosphoramidites are used as starting materials and may be synthesized as described by Beaucage *et al.*, *Tetrahedron Letters* 22: 1859 (1981) and U.S. Patent No. 4,458,066.

Nucleic acids, e.g., probes, also can be recombinantly produced through the use of plasmids or other vectors. Accordingly, this invention also provides vectors,
25 i.e., recombinant nucleic acid molecules comprising expression control sequences operatively linked to a nucleotide sequence encoding a region of the RNA component of telomerase.

Vectors can be adapted for function in prokaryotes or eukaryotes by inclusion of appropriate promoters, replication sequences, selectable markers, etc. for
30 replication and transcription of a nucleotide sequence. The construction of vectors and the replication and expression of genes in transfected cells involves the use of molecular cloning techniques also well known in the art (*see, e.g.*, Ausubel *et al.*, *supra*; Sambrook *et al.*, *supra*; Berger & Kimmel, volume 52, *Methods in Enzymology, Guide to*

Molecular Cloning Techniques (1987)). The particular vector used to transport the genetic information into the cell is also not particularly critical. The vector containing the sequence of interest is transformed into host cells for replication and expression. The particular procedure used to introduce the genetic material into the host cell is not particularly critical. It is only necessary that the particular procedure utilized be capable of successfully introducing at least one gene into the host cell which is capable of expressing the gene (see generally Sambrook *et al.*, *supra*; Ausubel, *et al.*, *supra*.

For delivery into cells or for gene therapy methods, recombinant production of inhibitory polynucleotides through the use of expression vectors is particularly useful. Accordingly, this invention also provides expression vectors, e.g., recombinant nucleic acid molecules comprising expression control sequences operatively linked to the nucleotide sequence encoding the inhibitory polynucleotide. Expression vectors can be adapted for function in prokaryotes or eukaryotes (e.g., bacterial, mammalian, yeast, *Aspergillus*, and insect cells) by inclusion of appropriate promoters, replication sequences, markers, etc. for transcription and translation of mRNA. The construction of expression vectors and the expression of genes in transfected cells involves the use of molecular cloning techniques also well known in the art (Sambrook *et al.*, *supra*; Ausubel *et al.*, *supra*; and Berger & Kimmel, *supra*). Useful promoters for such purposes include a metallothionein promoter, a constitutive adenovirus major late promoter, a dexamethasone-inducible MMTV promoter, a SV40 promoter, a MRP pol III promoter, a constitutive MPSV promoter, a tetracycline-inducible CMV promoter (such as the human immediate-early CMV promoter), and a constitutive CMV promoter. A plasmid useful for gene therapy can comprise other functional elements, such as selectable markers, identification regions, and other genes. Recombinant DNA expression plasmids can also be used to prepare the polynucleotides of the invention for delivery by means other than by gene therapy, although it may be more economical to make short oligonucleotides by *in vitro* chemical synthesis.

Methods of transfecting genes into mammalian cells and obtaining their expression for *in vitro* use or for gene therapy, are well known to the art (see, e.g., *Methods in Enzymology*, vol. 185 (Goeddel, ed. 1990); Krieger, *Gene Transfer and Expression -- A Laboratory Manual* (1990)). Cells can be transfected with plasmid vectors, for example, by electroporation. Cells can be transfected with polynucleotides

by calcium phosphate precipitation DNA liposome complexes, by particle-mediated gene transfer (biolistics) or with liposomes:

Expression vectors useful in this invention depend on their intended use. Such expression vectors must, of course, contain expression and replication signals compatible with the host cell. Expression vectors useful for expressing the inhibitory polynucleotide of this invention include viral vectors such as retroviruses, adenoviruses and adeno-associated viruses, plasmid vectors, cosmids, liposomes and the like. Viral and plasmid vectors are preferred for transfecting mammalian cells. The expression vector pcDNA1 (Invitrogen, San Diego, CA), in which the expression control sequence comprises the CMV promoter, provides good rates of transfection and expression. Adeno-associated viral vectors are useful in the gene therapy methods of this invention.

V. INHIBITORY POLYNUCLEOTIDES

A. General

This invention provides inhibitory polynucleotides directed against the RNA component of telomerase that inhibit telomerase activity. Inhibitory polynucleotides can inhibit telomerase activity in a number of ways. According to one mechanism, the polynucleotide prevents transcription of the telomerase RNA component gene (for instance, by triple helix formation). In another mechanism, the polynucleotide destabilizes the telomerase RNA component and reduces its half-life. In another mechanism, the polynucleotide inhibits assembly of the RNA component into the telomerase ribonucleoprotein by binding to the RNA component of telomerase. In another mechanism, the polynucleotide inhibits the polymerase activity of the telomerase ribonucleoprotein, e.g., by binding to an accessible region in telomerase or by inhibiting the polymerase activity of telomerase.

An inhibitory polynucleotide is a polynucleotide that is capable of hybridizing under stringent conditions with a target polynucleotide and that interferes with the transcription, processing, translation or other activity of the target polynucleotide. Inhibitory polynucleotides generally are single-stranded and have a sequence of at least 7, 8, 9, 10, or 11 nucleotides capable of specifically hybridizing to the target sequence. RNA sequences generally require a sequence of at least 10 nucleotides for specific hybridization. Inhibitory polynucleotides include, without

limitation, antisense molecules, ribozymes, sense molecules and triplex-forming molecules.

While not wishing to be limited by theory, it is believed that inhibitory polynucleotides inhibit the function of a target, in part, by binding to the appropriate target sequence. An inhibitory polynucleotide can inhibit DNA replication or DNA transcription by, for example, interfering with the attachment of DNA or RNA polymerase to the promoter by binding to a transcriptional initiation site or a template. It can interfere with processing of mRNA, poly(A) addition to mRNA or translation of mRNA by, for example, binding to regions of the RNA transcript such as the ribosome binding site. It can promote inhibitory mechanisms of the cells, such as promoting RNA degradation via RNase action. The inhibitory polynucleotide can bind to the major groove of the duplex DNA to form a triple helical or "triplex" structure. Methods of inhibition using inhibitory polynucleotides therefore encompass a number of different approaches to altering expression of specific genes that operate by different mechanisms. These different types of inhibitory polynucleotide technology are described in Helene & Toulme, *Biochim. Biophys. Acta*. 1049: 99-125 (1990).

The literature also provides examples of antisense polynucleotide inhibition of the function of ribonucleoproteins. Hence, for ribonucleoprotein complexes that contain a functional RNA (e.g., snRNP complexes involved in RNA splicing), it has been shown that antisense polynucleotides can inhibit *in vitro* activity (e.g., splicing). Therefore, the polynucleotides of the invention, among other applications, are useful for detecting and inhibiting telomerase by binding to accessible regions of the RNA component in the native telomerase ribonucleoprotein.

B. Antisense

This invention provides antisense polynucleotides capable of specifically hybridizing to a target sequence of the RNA component of telomerase, e.g., hTR. Antisense polynucleotides are useful *in vitro* or *in vivo* to inhibit the activity of telomerase. Administration of the antisense reagents of the invention to a target cell results in reduced telomerase activity, and is particularly useful for treatment of diseases characterized by high telomerase activity (e.g., cancers). Without intending to be limited to any particular mechanism, it is believed that antisense oligonucleotides bind to, and interfere with the translation of, the sense mRNA; render RNA susceptible to nuclease

digestion; interfere with transcription, interfere with processing, localization or otherwise with RNA precursors ("pre-mRNA"); repress transcription of mRNA from the hTR gene, or act through some other mechanism. However, the particular mechanism by which the antisense molecule reduces hTR expression is not critical.

5 The antisense polynucleotides of this invention comprise an antisense sequence of at least 7 nucleotides that specifically hybridize to a sequence from the RNA component of telomerase and, more particularly, mammalian telomerase and human telomerase. In one aspect of the invention, the RNA sequence to which the antisense sequence specifically hybridizes is within an accessible region of the telomerase RNA
10 component. For example, the accessible region can be selected from the range of nucleotides 137-196, 290-319, or 350-380 of hTR. In one embodiment, the antisense polynucleotide does not hybridize to a sequence within the template region of telomerase RNA.

 The antisense sequence can be between about 10 and about 50 nucleotides
15 or between about 15 and about 35 nucleotides. In one embodiment, the sequence of the polynucleotide contains within it the antisense sequence. In this case, the antisense sequence is contained within a polynucleotide of longer sequence. In another embodiment, the sequence of the polynucleotide consists essentially of, or is, the antisense sequence. Thus, for example, the antisense polynucleotide can be a
20 polynucleotide of less than about 50 nucleotides in a sequence that specifically hybridizes to the target sequence, e.g., an accessible region of the RNA component of telomerase. In other embodiments, antisense polynucleotides are polynucleotides of less than about 100 nucleotides or less than about 200 nucleotides. In general, the antisense polynucleotide should be long enough to form a stable duplex but short enough,
25 depending on the mode of delivery, to administer *in vivo*, if desired. The minimum length of a polynucleotide required for specific hybridization to a target sequence depends on several factors, such as G/C content, positioning of mismatched bases (if any), degree of uniqueness of the sequence as compared to the population of target polynucleotides, and chemical nature of the polynucleotide (e.g., methylphosphonate
30 backbone, peptide nucleic acid, phosphorothioate), among other factors.

 Generally, to assure specific hybridization, the antisense sequence is substantially complementary to the target RNA component of telomerase sequence. In certain embodiments, the antisense sequence is exactly complementary to the target

sequence. The antisense polynucleotides may also include, however, nucleotide substitutions, additions, deletions, transitions, transpositions, or modifications, or other nucleic acid sequences or non-nucleic acid moieties so long as specific binding to the relevant target sequence corresponding to target RNA component of telomerase or its gene is retained as a functional property of the polynucleotide.

The invention also provides an antisense polynucleotide that has sequences in addition to the antisense sequence (i.e., in addition to anti-RNA component of telomerase sequence). In this case, the antisense sequence is contained within a polynucleotide of longer sequence that acts e.g., as a detectable moiety by binding to a second nucleic acid sequence. In another embodiment, the sequence of the polynucleotide consists essentially of, or is, the antisense sequence.

The antisense nucleic acids (DNA, RNA, modified, non-naturally occurring, synthetic, analogues, and the like) can be made using any suitable method for producing a nucleic acid, such as the chemical synthesis and recombinant methods disclosed herein. In one embodiment, for example, antisense RNA molecules of the invention may be prepared by *de novo* chemical synthesis or by cloning. For example, an antisense RNA that hybridizes to the RNA component of telomerase can be made by inserting (ligating) an RNA component of telomerase sequence (e.g., SEQ ID NO:1, or fragment thereof) in reverse orientation operably linked to a promoter in a vector (e.g., plasmid). Provided that the promoter and, preferably termination and polyadenylation signals, are properly positioned, the strand of the inserted sequence corresponding to the noncoding strand will be transcribed and act as an antisense oligonucleotide of the invention.

The antisense oligonucleotides of the invention can be used to inhibit telomerase activity in cell-free extracts, cells, and animals, including mammals and humans. The antisense polynucleotides of the invention are also useful for inhibiting or detecting the RNA component of telomerase when it is in a native state (For general methods relating to antisense polynucleotides, see *Antisense RNA and DNA*, D.A. (Melton, ed., 1988); Dagle *et al.*, *Nucleic Acids Research* 19: 1805 (1991); and for a review of antisense therapy, see, e.g., Uhlmann *et al.*, *Chem. Reviews* 90: 543-584 (1990)).

Antisense oligonucleotides directed against the sequence of the RNA component of telomerase are also described in United States Applications 08/272,102,

filed July 7, 1994; 08/472,802, filed June 7, 1995; 08/521,634, filed August 31, 1995; 08/630,019, filed April 9, 1996; International Application PCT/US95/08530, filed July 6, 1995; and United States patent no. 5,583,016. Particularly useful antisense polynucleotides of the invention include those presented in Table 2 and Example 2, e.g.,
5 SEQ ID NOS:2-14.

Accordingly, a sequence of the antisense polynucleotide can specifically hybridize to all or part of the telomerase RNA component sequence, such as antisense polynucleotides to the human telomerase RNA component gene or its transcribed RNA, including truncated forms which may be associated with telomerase ribonucleoprotein.

10 Telomerase RNA component expression (transcription rate and/or RNA stability) is associated with activation and enzymatic activity of telomerase ribonucleoprotein. Therefore, antisense polynucleotides that prevent transcription of RNA corresponding to telomerase RNA component; the interaction of telomerase RNA component with the protein components of human telomerase and/or the interaction of
15 telomerase RNA component with telomeric sequences inhibit telomerase activity. Inhibiting telomerase activity is useful to inhibit immortalization or neoplastic transformation of cells expressing telomerase activity in the absence of antisense polynucleotides (For general methods relating to antisense polynucleotides, see, e.g., *Antisense RNA and DNA*, (Melton, ed., 1988); for a review of antisense therapy, see,
20 e.g., Uhlmann *et al.*, *Chem. Reviews*, 90: 543-584 (1990)).

The formation of a double-stranded polynucleotide resulting from hybridization of an antisense DNA molecule to the RNA component of telomerase renders the RNA component susceptible to RNase H cleavage. Accordingly, antisense polynucleotides directed against the RNA component of telomerase are particularly
25 effective for inhibiting telomerase activity in cells or samples containing RNase H.

C. Ribozymes

Cleavage of the RNA component of telomerase can be induced by the use of ribozymes or catalytic RNA. In this approach, the ribozyme would contain naturally
30 occurring RNA (ribozymes), non-naturally occurring nucleic acids or synthetic nucleic acids with catalytic activity. Bratty *et al.*, *Biochim. Biophys. Acta.*, 1216:345-59 (1993) and Denhardt, *Ann. N.Y. Acad. Sci.* 660: 70-76 (1992) describe methods for making ribozymes. Ribozymes of the invention include those having characteristics of group I

intron ribozymes (Cech *et al.*, *Biotechnology* 13: 323 (1995)) and others of hammerhead ribozymes (Edgington *et al.*, *Biotechnology* 10: 256 (1992)). Ribozymes of the invention include those having cleavage sites such as GUA, GUU and GUC. Other optimum cleavage sites for ribozyme-mediated inhibition of telomerase activity in accordance with the present invention include those described in PCT publications WO 94/02595 and WO 93/23569.

Like the antisense and other polynucleotides described above, which bind to an RNA, a DNA, or a telomerase protein component, a ribozyme binds a target RNA, and it also specifically cleaves and thereby potentially inactivates a target RNA, such as the RNA component of telomerase. Such a ribozyme can comprise 5'- and 3'-terminal sequences complementary to the telomerase RNA. In one embodiment, the ribozyme is directed to an accessible region of the telomerase RNA component, e.g., not including the template region.

Depending on the site of cleavage, a ribozyme can render the telomerase enzyme inactive (*see* International application WO 93/23572). Upon review of the RNA sequence of the human telomerase RNA component those in the art will note that several useful ribozyme target sites are present and susceptible to cleavage by, for example, a hammerhead motif ribozyme. Optimum target sites for ribozyme-mediated inhibition of telomerase activity can be determined as described by Sullivan *et al.*, PCT patent publication No. 94/02595 and Draper *et al.*, PCT patent publication No. 93/23569. As described by Hu *et al.*, PCT publication WO 94/03596, antisense and ribozyme functions can be combined in a single oligonucleotide. Moreover, ribozymes can comprise one or more modified nucleotides or modified linkages between nucleotides, as described above in conjunction with the description of illustrative antisense oligonucleotides of the invention. In one aspect, a catalytic subunit of RNase P (human or *E. coli*) is modified (*see* Altman, *Biotechnology* 13: 327 (1995)) to generate a guide sequence which corresponds to the portion of mammalian telomerase RNA component which base-pairs to the telomere repeat sequence; such RNase P variants can cleave telomere sequences. In one aspect, a catalytic subunit of RNase P (human or *E. coli*) is modified to generate a guide sequence which is complementary to a portion of telomerase RNA component such that the RNase P variant can cleave telomerase RNA component.

Such engineered ribozymes can be expressed in cells or can be transferred by a variety of means (e.g., liposomes, immunoliposomes, biolistics, direct uptake into

cells, etc.). Short RNA oligonucleotides between 15 and 20 ribonucleotides in length corresponding to the region of the target RNA component of telomerase containing the cleavage site can be evaluated for secondary structural features that may render the oligonucleotide more desirable. The suitability of cleavage sites may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays, or by testing for *in vitro* ribozyme activity in accordance with standard procedures known in the art. In one embodiment, the ribozymes of the invention are generated *in vitro* and introduced into a cell or patient. In another embodiment, gene therapy methods are used for expression of ribozymes in a target cell *ex vivo* or *in vivo*.

D. Other Inhibitory Polynucleotides

In addition to the antisense and ribozyme inhibitory polynucleotides, one can construct polynucleotides that will bind to duplex nucleic acid either in the folded RNA component or in the gene for the RNA component, forming a triple helix-containing or triplex nucleic acid to inhibit telomerase activity. Such polynucleotides of the invention are constructed using the base-pairing rules of triple helix formation and the nucleotide sequence of the RNA component (Cheng *et al.*, *J. Biol. Chem.* 263: 15110 (1988); Ferrin & Camerini-Otero, *Science* 354: 1494 (1991); Ramdas *et al.*, *J. Biol. Chem.* 264: 17395 (1989); Strobel *et al.*, *Science* 254: 1639 (1991); Rigas *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 83: 9591 (1986)). Such polynucleotides can block telomerase activity in a number of ways, including by preventing transcription of the telomerase RNA component gene or by binding to a duplex region of the RNA component of telomerase in a manner that prevents the RNA component either from forming a functional ribonucleoprotein telomerase or from serving as a template for telomeric DNA synthesis.

Typically, and depending on mode of action, the triplex-forming polynucleotides of the invention comprise a sequence large enough to form a stable triple helix but small enough, depending on the mode of delivery, to administer *in vivo*.

In another aspect, the invention provides inhibitory polynucleotides comprising a portion of the sequence of the RNA component of telomerase. In one embodiment the polynucleotide has a sequence sufficient to bind to a protein component of telomerase, but not sufficient to create a functional telomerase ribonucleoprotein.

Such molecules are useful as decoys. Produced in sufficient quantities, they compete with functional RNA component for existing protein components, thereby decreasing the amount of functional telomerase, and telomerase activity, in a cell.

5 VI. METHODS OF INHIBITING TELOMERASE ACTIVITY

This invention provides methods of inhibiting telomerase activity either *in vitro* or *in vivo* by contacting telomerase with an inhibitory polynucleotide of the invention. Such methods are useful both in samples containing telomerase as well as in living cells, either cultured or *in vivo* in methods of treatment. In cells, inhibition of
10 telomerase activity renders an immortal cell mortal. Telomerase inhibition therapy is an effective treatment against cancers involving the uncontrolled growth of immortal cells. Delivery of inhibitory polynucleotides against the RNA component of telomerase prevent telomerase action and ultimately leads to cell senescence and cell death of treated cells.

In one method of the invention, inhibiting telomerase involves contacting
15 telomerase with an inhibitory polynucleotide directed against the template region of the RNA component of telomerase, and with an inhibitory polynucleotide directed against an accessible region of the RNA component of telomerase, but which does not specifically hybridize to the template region.

20 A. *In vitro*

The inhibitory polynucleotides of this invention are useful for inhibiting telomerase activity *in vitro*. Such methods are useful as controls in screening assays to identify other molecular inhibitors of telomerase activity. The methods involve contacting the telomerase with an inhibitory polynucleotide of this invention, for
25 example, by adding it to a control telomerase sample. In parallel, an potential inhibitor is added to a test telomerase sample. The level of inhibition of telomerase in the test sample is then compared to that of the control sample to evaluate the efficacy of the inhibitory molecule being tested.

30 B. *In vivo*

Inhibitory polynucleotides against telomerase are useful for inhibiting telomerase activity in both cultured cells and in cells *in vivo*. Inhibiting telomerase activity in cultured cells is useful for mortalizing those cells. For example, immortal cell

lines can be made mortal. Immortalized cells from a subject can be mortalized by the introduction of an inhibitory polynucleotide and then re-introduced into a subject in a prophylactic or therapeutic treatment of a subject. The inhibition of telomerase activity in cells *in vivo* is useful in prophylactic and therapeutic methods of treating cancer and other disorders involving over-expression of telomerase.

This invention contemplates a variety of means for delivering an inhibitory polynucleotide to a subject including, for example, direct uptake of the molecule by a cell from solution, facilitated uptake through lipofection (e.g., liposomes or immunoliposomes), particle-mediated transfection, and intracellular expression from an expression cassette having an expression control sequence operably linked to a nucleotide sequence that encodes the inhibitory nucleic acid.

One can provide a cell with an inhibitory polynucleotide by contacting the cell with a soluble inhibitory nucleic acid, for example, in the culture medium *in vitro* or in the circulatory system, interstitial fluid or tissue mass *in vivo*. Soluble inhibitory nucleic acids present in the external milieu have been shown to gain access to the cytoplasm. Methods useful for delivery of polynucleotides for therapeutic purposes are described in Inouye *et al.*, U.S. Patent 5,272,065.

VII. PROPHYLACTIC AND THERAPEUTIC METHODS

This invention provides methods of treating conditions in mammals involving undesirable expression of telomerase activity. The methods involve administering to the subject an amount of an inhibitory polynucleotide of this invention effective to inhibit telomerase activity (a pharmacologically effective amount). Cells that express telomerase activity and that can be targets of telomerase inhibition therapy include telomerase expressing cancer cells, germ-line cells and telomerase expressing hematopoietic cells. Inhibiting telomerase activity is also useful in treating veterinary proliferative diseases. Because telomerase is active in a limited number of cell types, e.g., tumor cells, germline cells, certain stem cells of the hematopoietic system, T and B cells, sun-damaged skin, and proliferative cervix, most normal cells are not affected by telomerase inhibition therapy. Steps can also be taken to avoid contact of the telomerase inhibitor with germline or stem cells, if desired, although this may not be essential.

A. Cancer

The mechanisms that control the cell cycle in normal cells go awry in cancer cells. Consequently, these cells continue to divide when normal cells would not divide. Most cancer cells exhibit telomerase activity. These cells, therefore, maintain the ability to divide after the number of cell divisions in which normal somatic cells usually reach senescence. Thus, inhibition of telomerase activity in telomerase-expressing cancer cells results in eventual cell crisis and senescence. Inhibitory polynucleotides that inhibit telomerase activity are useful in treating or preventing cancer. Types of cancer that can be treated include, for example, adenocarcinoma of the breast, prostate, and colon; all forms of bronchogenic carcinoma of the lung; leukemias such as mixed cell, T-cell chronic, lymphocytic acute, lymphocytic chronic, and myeloid; Hodgkin's disease; melanoma; hepatoma; neuroblastoma; and papilloma.

B. Germ-line Cells

Germ-line cells, i.e., oocytes and sperm, express telomerase activity. Therefore, inhibition of telomerase activity in germ-line cells is useful for methods of contraception or sterilization.

C. Hematopoietic Stem Cells

A subpopulation of normal hematopoietic cells (e.g., B and T cells) and hematopoietic stem cells express telomerase. Therefore, inhibition of telomerase in such cells is useful for immunosuppression and for selectively down-regulating specific branches of the immune system, e.g., a specific subset of T cells. Such methods are useful in anti-inflammatory therapies. Inhibiting telomerase in certain branches of cells using inhibitory polynucleotides is attractive because after therapeutic effect, the treatment can be halted and stem cells will repopulate the system with healthy cells.

D. Infection by Eukaryotic Organisms

Eukaryotic organisms that express telomerase, e.g., yeast, parasites, and fungi, can infect the body. Such infections can be treated by inhibiting telomerase in these organisms, thereby halting growth of the organism.

E. Administration

Inhibitory polynucleotides and vectors for expressing them can be delivered conveniently in the form of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the agent. The pharmaceutical composition can be administered by any means known in the art for delivery of such molecules. However, systemic administration by injection is preferred. This includes intramuscular, intravenous, intraperitoneal, and subcutaneous injection. The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms for parenteral administration include unit doses of injectable solutions.

The form, amounts and timing of administration generally are a matter for determination by the practitioner. In one embodiment, the pharmaceutical composition is an expression vector composition delivered as a unit dosage form. Dosages include about 10^7 to 10^{13} vector molecules per ml of carrier. The volume administered can be selected by the practitioner. According to one embodiment of this invention, approximately 10^{10} vectors suspended in about 1 ml of sterile PBS constitute a therapeutically effective amount.

VIII. PURIFICATION OF TELOMERASE

Antisense polynucleotides directed against accessible regions of the RNA component of telomerase are useful as affinity reagents for purifying telomerase. Such methods involve immobilizing the antisense polynucleotide on a solid support, contacting the telomerase with the antisense polynucleotide, removing molecules not bound to the support, and isolating telomerase from the support. Methods for purifying telomerase using affinity reagents are described in U.S. patent application 08/510,736, filed August 4, 1995.

IX. METHODS OF DETECTING THE RNA COMPONENT OF TELOMERASE

The method of detecting the presence, absence or amount of the RNA component of telomerase in a sample involves two steps: (1) specifically hybridizing a polynucleotide to an accessible region of the RNA component of telomerase, and (2) detecting the specific hybridization. Detection refers to determining the presence,

absence, or amount of the RNA component of telomerase in a sample, and can include quantitation of the amount of RNA component of telomerase per cell in a sample.

For the first step of the method, the polynucleotide used for specific hybridization is chosen to hybridize to any suitable region of the RNA component of telomerase. In one embodiment, the region is an accessible region, excluding the template region. Such polynucleotides allow efficient detection of hTR in cell extracts and tissue samples, as described herein. The polynucleotide can be a DNA or RNA molecule, as well as a synthetic, non-naturally occurring analog of the same. The polynucleotides in this step are polynucleotide primers and polynucleotide probes. Suitable primer lengths are from 7-50 nucleotides, preferably from 10-40 nucleotides, and most preferably from 15-35 nucleotides. Specific hybridization conditions are selected by those skilled in the art, as discussed herein.

For the second step of the reaction, any suitable method of detecting specific hybridization of a polynucleotide to the RNA component of telomerase may be used. Such methods include, e.g., amplification by extension of a hybridized primer using reverse transcriptase (RT); extension of a hybridized primer using RT-PCR or other methods of amplification; and *in situ* detection of a hybridized primer (*see, e.g.*, Patent Application No. 08/482,115, filed June 7, 1995). Detectable moieties used in these methods include, e.g., labeled polynucleotide probes; direct incorporation of label in amplification or RT reactions, and labeled polynucleotide primers.

A. Reverse Transcription

A first method for detecting specific hybridization of a polynucleotide to the RNA component of telomerase is reverse transcription. Reverse transcription is an amplification method that copies RNA into DNA. The reverse transcription reaction, which synthesizes first strand cDNA, is performed by mixing RNA with random hexamer primer or a specific primer, heating to 95°C for 5 minutes to denature the nucleic acids (the thermal cycler may be used for this step), and then cooling on ice. The reaction mixture, prepared according to the enzyme manufacturers instructions or according to kit instructions, is added to the denatured RNA and hexamer mixture and incubated at a suitable temperature, usually 42°C. The reaction is stopped by heating the tube containing the reaction mixture for 10 minutes at 95°C. The first strand cDNA is

collected by precipitation and brief centrifugation and aliquoted to new tubes, in which it can be quickly frozen on dry ice and stored at -80°C, if necessary, for later use.

B. RT-PCR

5 Methods of amplification reactions, e.g., PCR (polymerase chain reaction) or LCR (ligase chain reaction) are known in the art (*PCR Technology: Principles and Applications for DNA Amplification* (Erlich, ed., 1989); *PCR Protocols: A Guide to Methods and Applications* (Innis *et al.* eds., 1990); Mattila *et al.*, *Nucleic Acids Res.* 19: 4967 (1991); Eckert & Kunkel, *PCR Methods and Applications* 1: 17 (1991); and the
10 U.S. Patents referenced above). Optimal reverse transcription, hybridization, and amplification conditions will vary depending upon the sequence composition and length(s) of the targeting polynucleotide(s) primers and target(s) employed, and the experimental method selected by the practitioner. Various guidelines may be used to select appropriate primer sequences and hybridization conditions (*see, e.g.,* Sambrook *et al.*,
15 *supra*).

 PCR is typically carried out in a buffered aqueous solution, preferably at a pH of 7-9. Deoxyribonucleoside triphosphates are added to the synthesis mixture in adequate amounts, and the resulting solution may be heated to about 85-100°C for about 1 to 10 minutes. After this optional heating period, the solution is allowed to cool to
20 about 20-40°C, for primer hybridization. An agent for polymerization is added to the mixture, and the reaction is allowed to occur under conditions known in the art, typically using a thermocycler. This synthesis reaction may occur at room temperature up to a temperature just over which the agent for polymerization no longer functions efficiently. The agent for polymerization may be any compound or system that will function to
25 accomplish the synthesis of primer extension products, including enzymes. Suitable enzymes for this purpose include, for example, *E. coli* DNA polymerase I or Klenow fragment, *Taq* DNA polymerase, and other available DNA polymerases. A preferred embodiment of detection uses an RT-PCR protocol, as described in Example 1. RT-PCR combines reverse transcription of RNA into DNA and subsequent DNA amplification
30 reactions in a single reaction.

C. In Situ Hybridization

Identification of cells, typically in a mixed population, that express the RNA component of telomerase can be performed by *in situ* hybridization. A sample of tissue or cells is fixed onto a glass slide and permeablized sufficiently for use with *in situ* hybridization techniques, according to standard methods. After the sample is fixed, a probe or primer that specifically hybridizes to the RNA component of telomerase is hybridized to the sample, and then the hybridization of the probe or primer is detected, for example, using an RT-PCR protocol or other methods described herein.

D. Detectable Moieties

These methods of detecting hybridization, described above, generally include the use of a detectable moiety. Primers and probes that include detectable moieties are synthesized by standard methods known to those skilled in the art (*see* Ausubel; *et al.*, and Sambrook, *et al.*, *supra*). The detectable moiety may be directly or indirectly detectable and associated with either a primer or a probe. Directly detectable moieties include, e.g., polynucleotides that are labeled with ^{32}P at the 5' end of the molecule (see Example 1), or that incorporate radioactive nucleotides. Indirectly detectable moieties include, for example, polynucleotides that incorporate biotinylated nucleotides recognized by streptavidin, or a nucleotide sequence, which is the binding partner for a radioactively labeled complementary sequence.

The detectable moiety often generates a measurable signal, such as a radioactive, chromogenic, or fluorescent signal, that can be used to quantitate the amount of bound detectable moiety, for example, for determination of a diagnostic value or a prognostic value for hTR in a sample. Quantitation of the signal is achieved by methods known to those skilled in the art, for example, scintillation counting, densitometry, or flow cytometry. Determination of such a diagnostic value or a prognostic value allows comparison with a value for hTR in a normal cell sample. Using this comparison, a diagnosis or prognosis regarding the patient's sample may be determined.

X. CO-AMPLIFICATION

Often, cell extracts or tissue samples used in methods of determining the amount of the RNA component of telomerase in a sample will contain variable amounts of cells or extraneous extracellular matrix materials. In addition, the amplification

efficiency may vary from reaction to reaction. Thus, a method of determining the cell number in a sample is important for determining the relative or quantitative amount per cell of a test polynucleotide such as hTR. In addition, a method of determining amplification efficiency is important for determining the relative or quantitative amount of hTR in a sample. A control for cell number and amplification efficiency is useful for measuring quantitative amounts of a test polynucleotide (e.g., hTR) in a sample, for determining prognostic and diagnostic values for the sample. Previous work has used 28S rRNA as a control, by diluting reverse transcribed 28S rRNA and adding it to the amplification reaction (Khan *et al.*, *Neurosci. Lett.* 147: 114-117 (1992)).

This invention thus provides a method of quantitation of the amount in a sample of a test polynucleotide, for example, hTR, involving co-amplification of the test polynucleotide with a control polynucleotide in an RT-PCR reaction. Two or more polynucleotides may be co-amplified in a single reaction, even when the two polynucleotides are present in vastly different amounts. This method is a convenient method of quantitating the amount of hTR in a sample, because the RT and amplification reactions are carried out in the same reaction for a test and control polynucleotide. The co-amplification of the control polynucleotide allows normalization of the cell number in the sample as compared to the amount of hTR in the sample. This feature is particularly useful for diagnostic and prognostic methods for cancers because these values must be correlated with standard diagnostic and prognostic values for various cancers. Co-amplification with an internal control can also provide a standard for amplification efficiency.

Suitable control polynucleotides for co-amplification reactions include DNA, RNA expressed from housekeeping genes, constitutively expressed genes, and *in vitro* synthesized RNAs added to the reaction mixture. Endogenous control polynucleotides are those that are already present in the sample, while exogenous control polynucleotides are added to a sample, creating a "spiked" reaction. Suitable controls include, e.g., β -actin RNA, GAPDH RNA, snRNP RNA (RNA components of snRNPs), ribosomal RNA, and satellite DNA. A preferred embodiment of the control RNA is endogenously expressed 28S rRNA.

The control and test polynucleotides will often differ in their abundance in a cell. For the co-amplification method to be useful for quantitation, the control and test polynucleotides must both be amplified in a linear range. The co-amplification reaction

can be performed using an endogenous or exogenous control polynucleotide that is equally, more, or less abundant than the test polynucleotide. In a preferred embodiment, the control polynucleotide is more abundant than hTR, for example, 28S rRNA is about 10,000 times more abundant than hTR in cells.

5 To achieve linear amplification of both control and test polynucleotides in the same reaction when one target is considerably more abundant than the other, the primers for the more abundant target, such as 28S rRNA, can be designed so that they are less efficient for amplification. For example, the primers can contain mismatches at the 5' end so that reverse transcription of the control polynucleotide is less efficient due
10 to less efficient primer hybridization, and thus less efficient extension by RT. Another method of achieving less efficient hybridization is to create shorter control primers, which are less efficient both at the RT and at the amplification step. If the test polynucleotide is more abundant than the control, then primers are designed for the test polynucleotide so that so that the amplification of the test polynucleotide is less efficient,
15 as described above. Both of these methods can be used for the same primer, creating a control primer set that is about 10,000 fold less efficient both at the RT and the PCR steps.

The co-amplification method is typically carried out using an RT-PCR protocol, which can be performed according to methods known to those skilled in the art,
20 and for which kits are commercially available. Test cell or patient samples are obtained from convenient sources such as CHAPS cell extracts or total RNA (see Example 1). The initial reverse transcription reaction uses specific primers, as described herein, that can include mismatches at the 5' end to provide less efficient priming of the control primers. After the RT reaction, the subsequent PCR reaction occurs in the same tube,
25 using the same oligonucleotides. The control cDNA can also be amplified in a less efficient manner by using relatively short control primers (as compared to the hTR primers). Embodiments of control primers include SEQ ID NOS:15-24, with SEQ ID NOS:19 and 23 as preferred embodiments. Embodiments of hTR primers include SEQ ID NOS:25 and 26 (*see, e.g.*, Table I, which lists control and test polynucleotides).
30 Other suitable primers, which can also contain mismatches at the 5' end and relatively shorter lengths, can be determined by one skilled in the art. The primers for the RNA component of telomerase may be directed toward any convenient region of the sequence. For example, primers can be chosen that specifically hybridize to accessible regions of

hTR, such as nucleotides positions 137-196, 290-319, and 350-380 of hTR (see the hTR sequence, nucleotides 266-716 of the hTR gene in SEQ ID NO:1 and Figure 1 (SEQ ID NO:29)).

The RT-PCR products can be analyzed by polyacrylamide gel electrophoresis and visualization of the products, e.g., by autoradiography or fluorescence. RT-PCR co-amplification can also be carried out on tissue samples prepared for *in situ* hybridization, and the product visualized using a microscope. The *in situ* hybridized samples can also be quantitated, for example, by counting the fluorescent, radioactive, or chromogenic signal. After determining the amounts of the RNA component of telomerase in a sample, and the amounts of endogenous control in a sample, the amount of the RNA component of telomerase is normalized per cell, using the following formula: signal of test nucleic acid divided by signal of control nucleic acid. This normalized value is useful either as a diagnostic value, to be compared with the normalized amount of the RNA component in a normal sample, or an amount to be compared with a prognostic value. When exogenous internal controls are used in the co-amplification reaction, amplification efficiency can also be normalized as well as the amount of hTR per cell using the following formula: signal of test nucleic acid (hTR)/signal of internal control (hTR-IC) divided by signal of control nucleic acid (rRNA)/signal of internal control (28S rRNA-IC), e.g., $(hTR \div hTR-IC) / (28S \text{ rRNA} \div 28S \text{ rRNA-IC})$.

XI. DIAGNOSIS AND PROGNOSIS OF CANCER

Methods of determining whether a sample contains the RNA component of telomerase, and the amount of the RNA component, are particularly useful for diagnosis of cancer and determining its prognosis. In the diagnostic and prognostic methods of the invention, the assay is conducted to determine whether the RNA component of mammalian telomerase is present, whether the diagnostic value of the sample is higher than the value in a normal range of cells, and how the amount of the RNA component of telomerase in a sample compares to a prognostic value. Both the level of the RNA component and the presence or absence of the RNA component are used to determine the diagnostic and prognostic values for a given sample. The cells used to determine the normal range of RNA component expression can be normal cells from the individual to be tested, or normal cells from other individuals not suffering from a disease condition.

For diagnosis, preferably the control cells are normal adjacent cells from the same patient. For prognosis, typically the prognostic value is given as a range of RNA component amounts observed in a patient population in a given cancerous cell type. The determination of a diagnostic value of the RNA component of mammalian telomerase above normal range is indicative of the presence of immortal cells, such as certain types of cancer cells, and these values can be used to aid or make a diagnosis even when the cells would be classified as non-cancerous by pathology. Comparison of the amount of the RNA component of mammalian telomerase with a prognostic value for a given cancerous cell type allows staging of the cancer and determination of a prognosis. Thus, the methods of the present invention allows cancerous conditions to be detected with increased confidence and possibly at an earlier stage, before cells are detected as cancerous based on pathological characteristics.

The diagnostic and prognostic methods of the present invention can be employed with any cell or tissue type of any origin and can be used to detect an immortal or neoplastic cell, or tumor tissue, or cancer, of any origin, provided the cell expresses telomerase activity and therefore its RNA component. For patient samples (referring to a sample for hTR detection), the detection of immortal cells will typically be used to detect the presence of cancer cells of any of a wide variety of types, including solid tumors and leukemias. Types of cancer that may be detected include, for example, adenocarcinoma of the breast, prostate, and colon; all forms of bronchogenic carcinoma of the lung; leukemias such as mixed cell, T-cell chronic, lymphocytic acute, lymphocytic chronic, and myeloid; Hodgkin's disease; melanoma; hepatoma; neuroblastoma; and papilloma. Typically, *in situ* hybridization assays will be used for heterogenous or focal diseases such as breast and prostate cancer, while tube-based solution assays will be used for homogenous tumors such as neuroblastoma. In particular, the co-amplification method of the invention is useful for diagnostic and prognostic assays because it provides a method of determining the amount of hTR per cell. The quantitation allows comparison of patient sample values with standard prognostic and diagnostic values. In addition, quantitation via co-amplification is useful for determining the amount of hTR per cell in samples that contain extracellular materials.

The diagnostic and prognostic methods can also be carried out in conjunction with other diagnostic or prognostic tests. In some instances, such

combination tests can provide useful information regarding the progression of a disease, although the present methods of testing for hTR provide much useful information in this regard. When the present methods are used to detect the presence of cancer cells in patient's sample, the presence of hTR can be used to determine the stage of the disease, whether a particular tumor is likely to invade adjoining tissue or metastasize to a distant location, and whether a recurrence of the cancer is likely. Tests that may provide additional information include diagnostic tests for the estrogen receptor, progesterone receptor, DNA ploidy, fraction of cells in S-phase, nodal status, and presence of oncogene gene products.

Those of skill in the art will also recognize that a variety of patient samples can be used in the methods of the invention. For example, cell extracts, cultured cells, or tissue samples provide convenient samples for use with the methods of the invention. The methods of the invention can use samples either in solution or extracts, for example, with RT-PCR, or samples such as tissue sections for *in situ* methods of detection. Samples can also be obtained from sources such as cells collected from bodily fluids and wastes, e.g., urine, sputum, and blood; washes, e.g., bladder and lung; and fine-needle biopsies, e.g., from prostate, breast, and thyroid; cellular materials; whole cells; tissue and cell extracts; RNA extracted from tissue and cells; and histological sections of tissue.

The diagnostic and prognostic methods of the invention are carried out using methods of detecting the presence, absence or amount of the RNA component of mammalian telomerase, as described herein. A suitable cell sample is contacted with a polynucleotide that can specifically hybridize to the RNA component of mammalian telomerase, e.g., polynucleotides to accessible regions of hTR, and then the hybridization is detected using any of the methods described above. One embodiment of this method uses an RT-PCR protocol, and a preferred embodiment of the method uses co-amplification of hTR and a control RNA to provide a means of quantitation.

The present invention also provides for kits for performing the diagnostic and prognostic method of the invention. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise any one or more of the following materials: enzymes, reaction tubes, buffers, detergent, primers and probes that target hTR, primers and probes that target a control RNA such as 28S rRNA, control reagents, and instructions. A wide variety of kits and components can be

prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user. One such kit can include primers for RT-PCR of hTR, and/or *in situ* detection of hTR in a sample. In one embodiment, the kit includes oligonucleotide primers that are directed to an accessible region of hTR. A preferred kit
5 includes primers for co-amplification of hTR with a set of control primers such as 28S rRNA.

EXAMPLES

Example 1: RT-PCR Co-Amplification of hTR

10 The following examples are provided by way of illustration only and not by way of limitation. Those of skill will readily recognize a variety of noncritical parameters that could be changed or modified to yield essentially similar results.

hTR was co-amplified in an RT-PCR reaction with an internal control. This method is particularly useful for prognostic and diagnostic methods of hTR
15 detection because it provides an accurate and efficient method of quantitation of the amount of hTR per cell in a sample. In the first experiment, endogenous 28S rRNA was the control polynucleotide co-amplified with hTR. In the second experiment, 28S rRNA and hTR were amplified in separate tubes, with each RT-PCR reaction containing a corresponding *in vitro* synthesized internal control. The following primers were used in
20 the RT-PCR co-amplification reaction:

Table I

28S rRNA primers:

Forward: GCT AAA TAC CGG CAC GAG ACC GAT AG (SEQ ID NO:15)
 GCT AAA TAC CGG CAC GAG AC (SEQ ID NO:16)
 5 GCT AAA TAC CGG CAC GAG (SEQ ID NO:17)
 GAT CTA AAT ACC GGC ACG (SEQ ID NO:18)
 GAG CTA AAT ACC GGC ACG (SEQ ID NO:19)

Reverse: GGT TTC ACG CCC TCT TGA ACT CTC TC (SEQ ID NO:20)
 GTT TCA CGC CCT CTT GAA CTC (SEQ ID NO:21)
 10 GTT TCA CGC CCT CTT GAA C (SEQ ID NO:22)
 CTA GTT TCA CGC CCT CTT G (SEQ ID NO:23)
 CTG GTT TCA CGC CCT CTT G (SEQ ID NO:24)

hTR primers:

Forward: GAA GGG CGT AGG CGC CGT GCT TTT GC (SEQ ID NO:25)
 15 Reverse: GTT TGC TCT AGA ATG AAC GGT GGA AGG
 (SEQ ID NO:26)

A. Co-amplification with Endogenous 28S rRNA

20 Co-amplification with an endogenous control, for which a copy number is known or for which a standard curve can be created, provides a means of determining the amount of hTR per cell in a sample. In this example, endogenous 28S rRNA is used as a control in the RT-PCR co-amplification reaction.

Samples for the RT-PCR reaction were typically prepared by CHAPS extraction of cell samples, as described in Kim *et al.*, *Science* 266: 2011-2015 (1994), or
 25 RNA can be isolated by any standard method known to those skilled in the art. Cell types used for CHAPS extraction and co-amplification reactions include: HeLa, MCF7, 293, HT1080, BJ, and IMR90 (the latter two cell types are normal cells, the remainder are immortal or cancer cells). For CHAPS extract samples, 1 μ l of 1 μ g/ μ l total protein was used per reaction, or for isolated RNA samples, 1 μ l of 1 μ g/ μ l total RNA was used
 30 per reaction.

CHAPS extract samples were heat denatured for at least 5 minutes at 95°C before the RT-PCR reaction was initiated. This denaturation step may be combined with the RT-PCR cycling step. As a control for genomic DNA contamination, 10 units of

RNase per sample was added to selected samples, incubated for at least 10 minutes at 37°C, and then denatured for 10 minutes at 95°C.

The RT-PCR reactions (25 μ l) with CHAPS extracted samples were assembled as follows using the EZ rTth RNA PCR kit (Perkin Elmer): 7 μ l water, 5 μ l
5 5x EZ buffer, 3 μ l 2.5 μ M dNTPs, 2 μ l 25 μ M Mn(OAc)₂, 1 μ l rTth DNA polymerase, 1.5 μ l each reverse primer (20 μ M stock solution) (hTR and 28S rRNA primers), and 2 μ l each forward primer (20 μ M stock solution) (hTR and 28S rRNA primers).

The RT-PCR reaction described above was incubated in a thermocycler using the following conditions: (1) 1 cycle at 94°C for 5 minutes, (2) 1 cycle at 65°C
10 for 30 minutes (RT reaction), (3) 1 cycle at 94° for 1.5 minutes, and (4) 30 cycles of the following sequence: 94°C for 0.5 minute then 65°C for 1 minute followed by 72°C for 7 minutes. Reaction conditions may be adjusted according to the type of sample used, e.g., CHAPS extract or total RNA.

Reaction products were typically analyzed by gel electrophoresis, using a
15 12.5% polyacrylamide, 1x TBE gel. The reaction was also performed with one primer from each pair labeled with ³²P at the 5' end using γ ³²P-ATP, according to standard reaction conditions (*see, e.g., Sambrook et al., supra*). The amplification products were then detected by gel electrophoresis followed by autoradiography. Other standard
20 methods of labeling and types of labels may be used, for example, biotinylated labels, or staining with DNA dyes such as ethidium bromide or SYBR Green. If unlabeled primers are used, the amplification products may be detected by gel electrophoresis, blotting, and hybridization with a labeled polynucleotide probe.

The ratio between hTR and control 28S rRNA amplification products may be determined by densitometry scanning of an autoradiogram, or by any other suitable
25 method known to one skilled in the art, e.g., counting radioactivity, fluorescence or chromogenicity. The following formula was used to normalize the amount of hTR in a cell: signal of test nucleic acid (hTR) divided by signal of control nucleic acid (rRNA). The amount of hTR per sample according to this formula was used to determine diagnostic and prognostic values for a sample, and to determine the amount of hTR per
30 cell.

This experiment yielded the following results: The amplification efficiency of 28S rRNA was reduced by mismatches and shortened length introduced into the primer sets. The reduction of 28S rRNA amplification efficiency allowed co-

amplification of hTR, which is present at approximately 10,000 fold lower levels than 28S rRNA. In titrated Hela extracts, the level of 28S rRNA and hTR co-amplified in the same reaction decrease linearly, demonstrating that the assay can be used to quantitate the amount of hTR per cell.

5

B. Co-amplification with *In Vitro* Synthesized Internal Controls

Co-amplification of hTR with an internal control, in parallel with co-amplification of 28S rRNA with an internal control, provides a means for determining amplification efficiency. In addition, amount of 28S rRNA in the sample can be compared to a standard curve for that sample type, thus allowing a determination of the amount of hTR in a sample. In this example, exogenous controls are added to the RT-PCR co-amplification reaction.

In a second experiment, the hTR and 28S rRNA co-amplification reactions were performed in separate tubes, with *in vitro* synthesized internal controls added to each reaction. The hTR reaction contained hTR-IC (hTR internal control transcript) and the 28S rRNA reaction contained 28S rRNA-IC (28S rRNA internal control transcript). The reactions were assembled as described herein, except that each reaction contained an *in vitro* synthesized internal control, and one primer set (hTR or 28S rRNA) instead of two primer sets (hTR and 28S rRNA).

The RNA internal controls were synthesized *in vitro* using an RNA Polymerase Kit (Stratagene), according to the manufacturer's instructions. The RNA internal controls were isolated from the synthesis reaction according to standard procedures, and the concentration of each internal control was determined. Typically, 1 μ l of 0.2 μ g/ μ l 28S rRNA-IC, and 1 μ l of 4 ng/ μ l hTR-IC were added to each co-amplification reaction. These concentrations may be varied to determine the optimal concentration of the internal control.

The RT-PCR was assembled as described above except that 1 μ l of internal control was added per RT-PCR co-amplification reaction and one primer set was added to the reaction. After the co-amplification reaction was complete, reaction products were analyzed as described above. The following formula was used to determine amplification efficiency and quantitate the amount of hTR RNA per cell: signal of test nucleic acid (hTR)/signal of internal control (hTR-IC) divided by signal of

30

control nucleic acid (rRNA)/signal of internal control (28S rRNA-IC), e.g., $(\text{hTR} \div \text{hTR-IC}) / (28\text{S rRNA} \div 28\text{S rRNA-IC})$.

Example 2: Identification of Accessible Regions of hTR

5 A set of 17 contiguous antisense DNA oligonucleotides (30mers) were tested for their ability to direct RNase H cleavage of hTR in the context of the native telomerase enzyme. Three antisense DNA 30mers (denoted "14", "16", and "21") directed efficient cleavage of hTR, indicating that the corresponding regions of hTR were accessible to DNA probes in the intact ribonucleoprotein particle (RNP). Antisense
10 oligonucleotides "14," "16," and "21" (see Table II) were tested as potential inhibitors of human telomerase ("hTase"). These regions corresponded to nucleotides 350-380, 290-319 and 137-166 of hTR.

Preincubation of partially purified nuclear or cytoplasmic extract with antisense oligonucleotide "21" (directed against nucleotides 137 to 166 of hTR) resulted
15 in potent inhibition of hTase, as indicated by the standard primer elongation assay. Antisense oligonucleotides "14" and "16" and a "sense" oligonucleotide did not significantly affect hTase activity. A 20mer antisense oligonucleotide comprised of 2'-O-methyl RNA directed against nucleotides 147 to 166 of hTR also inhibited hTase. The concentration of antisense oligonucleotide that yielded 50% hTase inhibition (IC₅₀) was
20 estimated from an activity versus antisense oligo concentration profile. The IC₅₀s for the 20mer and 30mer antisense oligonucleotides were in the range of 1 to 10 nanomolar (antisense oligo:hTase at IC₅₀=3:1). Control antisense oligonucleotide yielded no inhibition of hTase at oligo concentrations of 600 to 2000 nanomolar. Northern analysis showed that hTR remained intact throughout the inhibition protocol, suggesting the
25 antisense inhibition of hTase was independent of RNase H activity.

The accessible regions were "fine mapped" by using shorter antisense oligonucleotides to direct RNase H cleavage of hTR. For the "14" region, a 20mer (14ab) and a 12mer (14d) directed RNase H cleavage. For the "16" region, two 20mers (16ab, 16bc) directed RNase H cleavage. For the "21" region, an antisense oligo as
30 small as 7 nucleotides directed RNase H cleavage within the 147-166 region of hTR. Hence, these "short" antisense oligonucleotides might also inhibit hTase. A map summarizing antisense sequences able to direct RNase H cleavage of hTR in the native RNP is shown in Figure 1.

Table II

5	Oligo #	Sequence	RNaseH Digestion?	Capture? (2'OMe)	Activity on beads	NB ref GLN -21
10	14	5' CGT TCC TCT TCC TGC GGC CTG AAA CGG TGA 3' (SEQ ID NO:2)	yes			73
	14ab	5' CGT TCC TCT TCC TGC GGC CT 3' (SEQ ID NO:3)	yes	yes	yes	92
	14bc	5' CCT GCG GCC TGA AAC GGT GA 3' (SEQ ID NO:27)	no	NA	NA	92
	14d	5' CGT TCC TCT TCC 3' (SEQ ID NO:4)	yes	yes	yes	106
	16	5' CTG ACA GAG CCC AAC TCT TCG CGG TGG CAG 3' (SEQ ID NO:5)	yes			73
	16ab	5' CTG ACA GAG CCC AAC TCT TC 3' (SEQ ID NO:6)	yes	yes	no	92
	16bc	5' CCA ACT CTT CGC GGT GGC AG 3' (SEQ ID NO:7)	yes	yes	NT	92
	21	5' GCT CTA GAA TGA ACG GTG GAA GGC GGC AGG 3' (SEQ ID NO:8)	yes			73, 13
	21ab	5' GCT CTA GAA TGA ACG GTG G 3' (SEQ ID NO:9)	yes	yes	*	177
	21ab3	5' GCT CTA GAA TGA ACG 3' (SEQ ID NO:10)	yes	NT	*	177
15	21ab2	5' GCT CTA GAA TG 3' (SEQ ID NO:11)	yes	yes	NT	177
	21ab1	5' GCT CTA G 3' (SEQ ID NO:12)	yes	yes	yes	177
	20/21	5' CAT TTT TTG TTT GCT CTA GA 3' SEQ ID NO:13)	yes	NT	NT	177
20	NA = not applicable NT = not tested * known to inhibit telomerase					

On the basis of the antisense data, biotinylated 2'OMe antisense RNA analogs were designed for affinity purification of telomerase. The goal of the antisense affinity approach was to design ligands that afforded good purification and yield, while keeping the enzyme intact (i.e., active). Several 2'OMe ligands met our criteria (Table II, Figure 1). The biotinylated 2'OMe analogs of 14ab and 14d, as well as the 21ab1 analog, "captured" active telomerase on streptavidin beads. These analogs were further refined via the synthesis of second generation antisense affinity ligands, which were designed to allow release of active telomerase (reversible ligands). Currently, our affinity scheme consists of two reversible antisense ligands, which are employed in series, and target two different regions of hTR. The first ligand is a disulfide version of

14ab which allows release of telomerase via dithiothreitol treatment. The second ligand contains the 21ab1 antisense sequence plus a tail of "nonsense" sequence. hTR is released from the antisense ligand by a displacement DNA oligonucleotide, which is complementary to the entire length of the 21ab1 antisense affinity ligand.

5 Oligo-decoration was used to further identify accessible regions of the telomerase ribonucleoprotein. Radioactively labeled 2'-methyl antisense polynucleotides were prepared and exposed to the telomerase ribonucleoprotein. The sample was incubated to allow the polynucleotide to bind to telomerase. Then the sample was run on a native gel. Polynucleotides that had bound to telomerase exhibited altered mobility on
10 the gel. In particular, polynucleotides RP2 and RP3 (Figure 1) were found to bind to the telomerase ribonucleoprotein. RP2 has the sequence CGG GCC AGC AGC TGA CA (SEQ ID NO:14). This demonstrated that nucleotides 167-193 are accessible to antisense polynucleotides. RP2 demonstrated an ability to capture telomerase on an affinity matrix and is useful for purifying telomerase.

15 The present invention provides novel methods for detecting the RNA component of telomerase. While specific examples have been provided, the above description is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification. The scope
20 of the invention should, therefore, be determined not with reference to the above description, but instead should be determined with reference to the appended claims along with their full scope of equivalents.

 All publications and patent documents cited in this application are incorporated by reference in their entirety for all purposes to the same extent as if each
25 individual publication or patent document were so individually denoted.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: Geron Corporation
(B) STREET: 230 Constitution Drive
(C) CITY: Menlo Park
(D) STATE: California
(E) POSTAL CODE (ZIP): 94025
(F) TELEPHONE: (415) 473-7700
(G) TELEFAX: (415) 473-7750
(H) TELEX:

(i) APPLICANT:

(A) NAME: Kim, Nam Woo
(B) STREET: 541 Winterberry Way
(C) CITY: San Jose
(D) STATE: California
(E) POSTAL CODE (ZIP): 95129
(F) TELEPHONE:
(G) TELEFAX:
(H) TELEX:

(i) APPLICANT:

(A) NAME: Wu, Fred
(B) STREET: 1143 Green Terrace
(C) CITY: Davis
(D) STATE: California
(E) POSTAL CODE (ZIP): 95616
(F) TELEPHONE:
(G) TELEFAX:
(H) TELEX:

(i) APPLICANT:

(A) NAME: Kealey, James T.
(B) STREET: 9 Mono Lane
(C) CITY: San Anselmo
(D) STATE: California
(E) POSTAL CODE (ZIP): 94960
(F) TELEPHONE:
(G) TELEFAX:
(H) TELEX:

(i) APPLICANT:

(A) NAME: Pruzan, Ronald
(B) STREET: 852 Matadero Avenue
(C) CITY: Palo Alto
(D) STATE: California
(E) POSTAL CODE (ZIP): 94306
(F) TELEPHONE:
(G) TELEFAX:
(H) TELEX:

(i) APPLICANT:

(A) NAME: Weinrich, Scott L.
(B) STREET: 1830 Brewster Avenue
(C) CITY: Redwood City
(D) STATE: California
(E) POSTAL CODE (ZIP): 94062
(F) TELEPHONE:
(G) TELEFAX:
(H) TELEX:

(ii) TITLE OF INVENTION: Methods for Detecting and Inhibiting the
RNA Component of Telomerase

- (iii) NUMBER OF SEQUENCES: 29
 - (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Townsend and Townsend and Crew LLP
 - (B) STREET: Two Embarcadero Center, Eighth Floor
 - (C) CITY: San Francisco
 - (D) STATE: California
 - (E) COUNTRY: USA
 - (F) ZIP: 94111-3834
 - (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
 - (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: WO PCT/US97/Not yet assigned
 - (B) FILING DATE: Not yet assigned
 - (C) CLASSIFICATION:
 - (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/770,564
 - (B) FILING DATE: 20-DEC-1996
 - (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/770,565
 - (B) FILING DATE: 20-DEC-1996
 - (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Storella, John R.
 - (B) REGISTRATION NUMBER: 32,944
 - (C) REFERENCE/DOCKET NUMBER: 15389-27PC
 - (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (415) 576-0200
 - (B) TELEFAX: (415) 576-0300
- (2) INFORMATION FOR SEQ ID NO:1:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 981 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (ix) FEATURE:
 - (A) NAME/KEY: -
 - (B) LOCATION: 1..981
 - (D) OTHER INFORMATION: /note= "PstI fragment of
SauIIIA1-HindIII fragment of clone 28-1
containing the sequence of the RNA
component of human telomerase (hTR) "
 - (ix) FEATURE:
 - (A) NAME/KEY: misc_RNA
 - (B) LOCATION: 266..716
 - (D) OTHER INFORMATION: /product= "RNA component of human
telomerase (hTR) "

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 311..320
- (D) OTHER INFORMATION: /note= "template region of hTR"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
CTGCAGAGGA TAGAAAAAAG GCCCTCTGAT ACCTCAAGTT AGTTTCACCT TTAAAGAAGG      60
TCGGAAGTAA AGACGCAAAG CCTTTCCCGG ACGTGCGGAA GGGCAACGTC CTTCTCATG      120
GCCGGAAAATG GAACTTTAAT TTCCCGTTCC CCCCAACCAG CCCGCCGAG AGAGTGACTC      180
TCACGAGAGC CGCGAGAGTC AGCTTGGCCA ATCCGTGCGG TCGGCGGCCG CTCCCTTTAT      240
AAGCCGACTC GCCCGGCAGC GCACCGGGTT GCGGAGGGTG GGCCTGGGAG GGGTGGTGGC      300
CATTTTTTGT CTAACCCTAA CTGAGAAGGG CGTAGGCGCC GTGCTTTTGC TCCCCGCGCG      360
CTGTTTTTCT CGCTGACTTT CAGCGGGCGG AAAAGCCTCG GCCTGCCGCC TTCCACCGTT      420
CATTCTAGAG CAAACAAAAA ATGTCAGCTG CTGGCCCGTT CGCCCCCTCCC GGGGACCTGC      480
GGCGGGTCGC CTGCCCAGCC CCCGAACCCC GCCTGGAGGC CGCGGTCGGC CCGGGGCTTC      540
TCCGGAGGCA CCCACTGCCA CCGCGAAGAG TTGGGCTCTG TCAGCCGCGG GTCTCTCGGG      600
GGCGAGGGCG AGGTTCAGGC CTTTCAGGCC GCAGGAAGAG GAACGGAGCG AGTCCCCGCG      660
CGCGGCGCGA TTCCCTGAGC TGTGGGACGT GCACCCAGGA CTCGGCTCAC ACATGCAGTT      720
CGCTTTCCTG TTGGTGGGGG GAACGCCGAT CGTGCGCATC CGTCACCCCT CGCCGGCAGT      780
GGGGGCTTGT GAACCCCCAA ACCTGACTGA CTGGGCCAGT GTGCTGCAAA TTGGCAGGAG      840
ACGTGAAGGC ACCTCCAAAG TCGGCCAAAA TGAATGGGCA GTGAGCCGGG GTTGCCCTGGA      900
GCCGTTCTTG CGTGGGTTCT CCCGTCTTCC GCTTTTTGTT GCCTTTTATG GTTGTATTAC      960
AACTTAGTTC CTGCTCTGCA G                                          981
```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..30
- (D) OTHER INFORMATION: /note= "oligo 14"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
CGTTCCTCTT CCTGCGGCCT GAAACGGTGA      30
```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..20
- (D) OTHER INFORMATION: /note= "oligo 14ab"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CGTTCCTCTT CCTGCGGCCT

20

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..12
- (D) OTHER INFORMATION: /note= "oligo 14d"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CGTTCCTCTT CC

12

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..30
- (D) OTHER INFORMATION: /note= "oligo 16"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CTGACAGAGC CCAACTCTTC GCGGTGGCAG

30

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..20
- (D) OTHER INFORMATION: /note= "oligo 16ab"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CTGACAGAGC CCAACTCTTC

20

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..20
- (D) OTHER INFORMATION: /note= "oligo 16bc"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CCAACTCTTC GCGGTGGCAG

20

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 30 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..30
- (D) OTHER INFORMATION: /note= "oligo 21"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GCTCTAGAAT GAACGGTGA AGGCGGCAGG

30

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..19
- (D) OTHER INFORMATION: /note= "oligo 2lab"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GCTCTAGAAT GAACGGTGG

19

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..15
- (D) OTHER INFORMATION: /note= "oligo 2lab3"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GCTCTAGAAT GAACG

15

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 11 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..11
- (D) OTHER INFORMATION: /note= "oligo 2lab2"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GCTCTAGAAT G

11

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..7
- (D) OTHER INFORMATION: /note= "oligo 21ab1"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GCTCTAG

7

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..20
- (D) OTHER INFORMATION: /note= "oligo 20/21"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CATTTTTTGT TTGCTCTAGA

20

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..17
- (D) OTHER INFORMATION: /note= "polynucleotide RP2"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CGGGCCAGCA GCTGACA

17

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- (ix) FEATURE:
 - (A) NAME/KEY: -
 - (B) LOCATION: 1..26
 - (D) OTHER INFORMATION: /note= "28S rRNA forward primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GCTAAATACC GGCACGAGAC CGATAG

26

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- (ix) FEATURE:
 - (A) NAME/KEY: -
 - (B) LOCATION: 1..20
 - (D) OTHER INFORMATION: /note= "28S rRNA forward primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GCTAAATACC GGCACGAGAC

20

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- (ix) FEATURE:
 - (A) NAME/KEY: -
 - (B) LOCATION: 1..18
 - (D) OTHER INFORMATION: /note= "28S rRNA forward primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GCTAAATACC GGCACGAG

18

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 18 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- (ix) FEATURE:
 (A) NAME/KEY: -
 (B) LOCATION: 1..18
 (D) OTHER INFORMATION: /note= "28S rRNA forward primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GATCTAAATA CCGGCACG

18

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 18 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- (ix) FEATURE:
 (A) NAME/KEY: -
 (B) LOCATION: 1..18
 (D) OTHER INFORMATION: /note= "28S rRNA forward primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GAGCTAAATA CCGGCACG

18

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- (ix) FEATURE:
 (A) NAME/KEY: -
 (B) LOCATION: 1..26
 (D) OTHER INFORMATION: /note= "28S rRNA reverse primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GGTTTCACGC CCTCTTGAAC TCTCTC

26

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..21
- (D) OTHER INFORMATION: /note= "28S rRNA reverse primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GTTTCACGCC CTCTTGAAC T

21

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..19
- (D) OTHER INFORMATION: /note= "28S rRNA reverse primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GTTTCACGCC CTCTTGAAC

19

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..19
- (D) OTHER INFORMATION: /note= "28S rRNA reverse primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CTAGTTTCAC GCCCTCTTG

19

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- (ix) FEATURE:
(A) NAME/KEY: -
(B) LOCATION: 1..19
(D) OTHER INFORMATION: /note= "28S rRNA reverse primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

CTGGTTTCAC GCCCTCTTG

19

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- (ix) FEATURE:
(A) NAME/KEY: -
(B) LOCATION: 1..26
(D) OTHER INFORMATION: /note= "hTR forward primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GAAGGGCGTA GCGCCGTGC TTTTGC

26

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- (ix) FEATURE:
(A) NAME/KEY: -
(B) LOCATION: 1..27
(D) OTHER INFORMATION: /note= "hTR reverse primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GTTTGCTCTA GAATGAACGG TGGAAGG

27

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..20
- (D) OTHER INFORMATION: /note= "oligo 14bc"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CCTGCGGCCT GAAACGGTGA

20

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..10
- (D) OTHER INFORMATION: /note= "template region of hTR"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

CTAACCCTAA

10

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 451 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..451
- (D) OTHER INFORMATION: /note= "RNA component of human telomerase (hTR) "

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 46..55
- (D) OTHER INFORMATION: /note= "template region of hTR"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GGGTTGCGGA	GGGTGGGCCT	GGGAGGGGTG	GTGGCCATTT	TTTGTCTAAC	CCTAACTGAG	60
AAGGGCGTAG	GCGCCGTGCT	TTTGCTCCCC	GCGCGCTGTT	TTTCTCGCTG	ACTTTCAGCG	120
GGCGGAAAAG	CCTCGGCCTG	CCGCCTTCCA	CCGTTCATTC	TAGAGCAAAC	AAAAAATGTC	180
AGCTGCTGGC	CCGTTGCCCC	CTCCCGGGGA	CCTGCGGCGG	GTCGCCTGCC	CAGCCCCCGA	240
ACCCCGCCTG	GAGGCCGCGG	TCGGCCCGGG	GCTTCTCCGG	AGGCACCCAC	TGCCACCGCG	300
AAGAGTTGGG	CTCTGTCAGC	CGCGGGTCTC	TCGGGGGCGA	GGGCGAGGTT	CAGGCCTTTC	360
AGGCCGCAGG	AAGAGGAACG	GAGCGAGTCC	CCGCGCGCGG	CGCGATTCCC	TGAGCTGTGG	420
GACGTGCACC	CAGGACTCGG	CTCACACATG	C			451

WHAT IS CLAIMED IS:

- 1 1. A polynucleotide comprising an antisense sequence of at least 7
2 nucleotides that specifically hybridizes to a nucleotide sequence within an accessible
3 region of the RNA component of a human telomerase ("hTR"), but that does not
4 hybridize to a sequence within the template region of hTR, wherein the sequence within
5 an accessible region is a sequence selected from nucleotides 137-196, 290-319, and 350-
6 380 of hTR.
- 1 2. The polynucleotide of claim 1, wherein the sequence is between 10
2 and 50 nucleotides in length.
- 1 3. The polynucleotide of claim 1 wherein the sequence is between 15
2 and 35 nucleotides in length.
- 1 4. The polynucleotide of claim 1 whose sequence consists essentially
2 of the sequence within an accessible region.
- 1 5. The polynucleotide of claim 1 comprising DNA or RNA.
- 1 6. The polynucleotide of claim 1 comprising a nucleotide analog
2 selected from phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl
3 phosphonates, 2'-O-methyl ribonucleotides and peptide-nucleic acids.
- 1 7. The polynucleotide of claim 1 further comprising an inhibitory
2 moiety.
- 1 8. The polynucleotide of claim 1 wherein the sequence is
2 complementary to the nucleotide sequence within an accessible region.
- 1 9. The polynucleotide of claim 1 which is at most 50 nucleotides long.

1 10. The polynucleotide of claim 1 of less than about 50 nucleotides in a
2 sequence that specifically hybridizes to an accessible region of the RNA component of
3 telomerase.

1 11. The polynucleotide of claim 1 whose nucleotide sequence is
2 selected from the group consisting of:

3 CGT TCC TCT TCC TGC GGC CTG AAA CGG TGA (SEQ ID NO:2)
4 CGT TCC TCT TCC TGC GGC CT (SEQ ID NO:3)
5 CGT TCC TCT TCC (SEQ ID NO:4)
6 CTG ACA GAG CCC AAC TCT TCG CGG TGG CAG (SEQ ID NO:5)
7 CTG ACA GAG CCC AAC TCT TC (SEQ ID NO:6)
8 CCA ACT CTT CGC GGT GGC AG (SEQ ID NO:7)
9 GCT CTA GAA TGA ACG GTG GAA GGC GGC AGG (SEQ ID NO:8)
10 GCT CTA GAA TGA ACG GTG G (SEQ ID NO:9)
11 GCT CTA GAA TGA ACG (SEQ ID NO:10)
12 GCT CTA GAA TG (SEQ ID NO:11)
13 GCT CTA G (SEQ ID NO:12)
14 CAT TTT TTG TTT GCT CTA GA (SEQ ID NO:13) and
15 CGG GCC AGC AGC TGA CA (SEQ ID NO:14).

1 12. An expression vector comprising a recombinant polynucleotide
2 comprising expression control sequences operatively linked with a nucleotide sequence
3 encoding a polynucleotide comprising an antisense sequence of at least 7 nucleotides that
4 specifically hybridizes to a nucleotide sequence within an accessible region of the RNA
5 component of a human telomerase ("hTR"), but that does not hybridize to a sequence
6 within the template region of hTR, wherein the sequence within an accessible region is a
7 sequence selected from nucleotides 137-196, 290-319, and 350-380 of hTR.

1 13. The expression vector of claim 12 wherein the expression control
2 sequences comprise a promoter selected from the metallothionein promoter, the
3 constitutive adenovirus major late promoter, the dexamethasone-inducible MMTV
4 promoter, the SV40 promoter, the MRP polIII promoter, the constitutive MPSV

5 promoter, the tetracycline-inducible CMV promoter (such as the human immediate-early
6 CMV promoter), and the constitutive CMV promoter.

1 14. The expression vector of claim 12 wherein the vector is a viral
2 vector or a plasmid vector comprising the recombinant polynucleotide.

1 15. The expression vector of claim 14 wherein the vector is a plasmid
2 vector contained in a liposome.

1 16. A pharmaceutical composition comprising a pharmaceutically
2 acceptable carrier and:

3 (1) a polynucleotide comprising an antisense sequence of at least 7
4 nucleotides that specifically hybridizes to a nucleotide sequence within an accessible
5 region of the RNA component of a human telomerase ("hTR"), but that does not
6 hybridize to a sequence within the template region of hTR, wherein the sequence within
7 an accessible region is a sequence selected from nucleotides 137-196, 290-319, and 350-
8 380 of hTR, or

9 (2) an expression vector comprising expression control sequences
10 operatively linked to a nucleotide sequence encoding the polynucleotide which vector
11 expresses the polynucleotide.

1 17. A method of inhibiting human telomerase activity comprising the
2 step of contacting human telomerase with a polynucleotide comprising an antisense
3 sequence of at least 7 nucleotides that specifically hybridizes to a nucleotide sequence
4 within an accessible region of the RNA component of a human telomerase ("hTR"), but
5 that does not hybridize to a sequence within the template region of hTR, wherein the
6 sequence within an accessible region is a sequence selected from nucleotides 137-196,
7 290-319, and 350-380 of hTR, whereby the polynucleotide inhibits the activity of the
8 telomerase.

1 18. The method of claim 17 wherein the antisense sequence is between
2 10 and 50 nucleotides in length.

1 19. The method of claim 17 wherein the antisense sequence is between
2 15 and 35 nucleotides in length.

1 20. The method of claim 17 wherein the step of providing the cell with
2 the polynucleotide comprises transfecting the cell with an expression vector comprising
3 expression control sequences operatively linked to a nucleotide sequence encoding the
4 antisense polynucleotide which vector expresses the polynucleotide.

1 21. The method of claim 17 wherein the cell is a cancer cell.

1 22. A method of treating a telomerase-related condition involving cells
2 exhibiting telomerase activity in a subject comprising the step of administering to the
3 subject an antisense polynucleotide in an amount effective to inhibit telomerase activity in
4 the cells, wherein the polynucleotide comprises a sequence of at least 7 nucleotides that
5 specifically hybridizes to a nucleotide sequence within an accessible region of the RNA
6 component of a human telomerase ("hTR"), but that does not hybridize to a sequence
7 within the template region of hTR, wherein the sequence within an accessible region is a
8 sequence selected from nucleotides 137-196, 290-319, and 350-380 of hTR, whereby
9 inhibiting telomerase activity in the cells provides the treatment of the condition.

1 23. The method of claim 22 wherein the telomerase-related condition is
2 cancer and inhibition of telomerase activity in the cancer cells inhibits the growth of the
3 cancer.

1 24. The method of claim 22 wherein the polynucleotide comprises a
 pharmaceutical composition.

1 25. The method of claim 24 wherein the pharmaceutical composition is
2 an injectable solution administered by injection.

1 26. The method of claim 22 wherein the polynucleotide comprises an
2 expression vector comprising expression control sequences operatively linked to a

3 nucleotide sequence encoding the polynucleotide which vector expresses the antisense
4 polynucleotide.

1 27. A method for detecting an RNA component of human telomerase
2 (hTR) in a sample, comprising the steps of:

3 (a) contacting the sample with a polynucleotide comprising a sequence of at
4 least 7 nucleotides that specifically hybridizes to a nucleotide sequence within an
5 accessible region of hTR but that does not specifically hybridize to a template region of
6 hTR, and

7 (b) detecting whether the polynucleotide has specifically hybridized to hTR;
8 whereby specific hybridization provides a detection of hTR in the sample.

1 28. The method of claim 27, wherein the sequence within an accessible
2 region is a sequence selected from nucleotide positions 137-196, 290-319, and 350-380
3 of hTR.

1 29. The method of claim 28, wherein the nucleotide sequence of the
2 polynucleotide is complementary to a nucleotide sequence of hTR within and including
3 nucleotide positions 137-196, 290-319, and 350-380.

1 30. The method of claim 28, wherein the polynucleotide is a nucleotide
2 analog selected from phosphorothioates, phosphoramidates, methyl phosphonates,
3 chiral-methyl phosphonates, 2'-O-methyl ribonucleotides, and peptide-nucleic acids.

1 31. The method of claim 28, wherein the polynucleotide is a
2 polynucleotide whose sequence is selected from the group consisting of:

3 CGT TCC TCT TCC TGC GGC CTG AAA CGG TGA (SEQ ID NO:2)

4 CGT TCC TCT TCC TGC GGC CT (SEQ ID NO:3)

5 CGT TCC TCT TCC (SEQ ID NO:4)

6 CTG ACA GAG CCC AAC TCT TCG CGG TGG CAG (SEQ ID NO:5)

7 CTG ACA GAG CCC AAC TCT TC (SEQ ID NO:6)

8 CCA ACT CTT CGC GGT GGC AG (SEQ ID NO:7)

9 GCT CTA GAA TGA ACG GTG GAA GGC GGC AGG (SEQ ID NO:8)

1 GCT CTA GAA TGA ACG GTG G (SEQ ID NO:9)
2 GCT CTA GAA TGA ACG (SEQ ID NO:10)
3 GCT CTA GAA TG (SEQ ID NO:11)
4 GCT CTA G (SEQ ID NO:12)
5 CAT TTT TTG TTT GCT CTA GA (SEQ ID NO:13) and
6 CGG GCC AGC AGC TGA CA (SEQ ID NO:14)

1 32. The method of claim 28, wherein detection comprises quantitating
2 the amount of hTR in the sample.

1 33. The method of claim 28, wherein the sample is prepared for *in situ*
2 detection.

1 34. The method of claim 28, wherein the sample comprises a
2 histological section of tissue.

1 35. The method of claim 28, wherein the polynucleotide comprises a
2 detectable moiety, and the step of detecting whether the polynucleotide has specifically
3 hybridized to hTR comprises detecting the moiety.

1 36. The method of claim 35, wherein the detectable moiety is attached
2 to a linker attached to the polynucleotide or wherein the detectable moiety is a linker.

1 37. The method of claim 35, wherein the detectable moiety is a
2 fluorescent label, a radioactive label, an enzymatic label, a biotinyl group, or an epitope
3 recognized by a secondary reporter.

1 38. The method of claim 28, wherein the polynucleotide is a primer
2 and the step of detecting whether the polynucleotide has specifically hybridized to hTR
3 comprises:

- 4 (a) initiating reverse transcription of hTR with the primer, and
5 (b) detecting an hTR reverse transcript;

1 whereby detection of the reverse transcript indicates that the polynucleotide has
2 specifically hybridized to hTR.

1 39. The method of claim 38, wherein the reverse transcription
2 comprises chain elongation of sequences complementary to hTR with a nucleotide
3 comprising a detectable moiety, and the step of detecting an hTR reverse transcript
4 comprises detecting the moiety, whereby the detection of the moiety provides a detection
5 of the reverse transcript.

1 40. The method of claim 39, wherein the detectable moiety is a
2 fluorescent label, a radioactive label, an enzymatic label, a biotinyl group, or an epitope
3 recognized by a secondary reporter.

1 41. The method of claim 38, wherein the step of detecting an hTR
2 reverse transcript comprises:

3 (a) contacting the sample with a polynucleotide probe comprising a detectable
4 moiety, and

5 (b) detecting hybridization between the probe and the reverse transcript by
6 detecting the moiety;

7 whereby hybridization between the polynucleotide probe and the reverse transcript
8 provides detection of the hTR reverse transcript.

1 42. The method of claim 41, wherein the detectable moiety is a
2 fluorescent label, a radioactive label, an enzymatic label, a biotinyl group, or an epitope
3 recognized by a secondary reporter.

1 43. The method of claim 38, wherein the step of detecting the reverse
2 transcript comprises the steps of amplifying a sequence of hTR from the reverse
3 transcript, and detecting an amplified hTR sequence and its complement; whereby
4 detection of an amplified hTR sequence and its complement provides detection of the
5 reverse transcript.

1 44. The method of claim 43, wherein the step of amplifying a sequence
2 of hTR comprises including a primer incorporating a nucleotide comprising a detectable
3 moiety, and the step of detecting an amplified hTR sequence and its complement
4 comprises detecting the moiety; whereby the detection of the moiety provides detection
5 of the amplified hTR sequence and its complement.

1 45. The method of claim 44, wherein the detectable moiety is a
2 fluorescent label, a radioactive label, an enzymatic label, a biotinyl group, or an epitope
3 recognized by a secondary reporter.

1 46. The method of claim 43, wherein the step of detecting an amplified
2 hTR sequence and its complement comprises:

3 (a) contacting the sample after the amplifying step with a polynucleotide probe
4 comprising a detectable moiety, and

5 (b) detecting hybridization between the probe and an amplified hTR sequence and
6 its complement by detecting the moiety;

7 whereby hybridization between the polynucleotide probe and the amplified hTR
8 sequence and its complement provides detection of the amplified hTR sequence and its
9 complement.

1 47. The method of claim 46, wherein the detectable moiety is a
2 fluorescent label, a radioactive label, an enzymatic label, a biotinyl group, or an epitope
3 recognized by a secondary reporter.

1 48. A method for diagnosing cancer in a patient, comprising the steps
2 of:

3 (a) determining a diagnostic value by detecting the RNA component of human
4 telomerase (hTR) in a patient sample, wherein detecting hTR comprises the steps of:

5 (i) contacting the sample with a polynucleotide that specifically hybridizes
6 to a nucleotide sequence within an accessible region of hTR but that does not specifically
7 hybridize to a template region of hTR, and

8 (ii) detecting specific hybridization of the polynucleotide to hTR;

1 whereby specific hybridization provides a determination that the sample contains
2 hTR, and
3 (b) comparing the diagnostic value with a normal range of hTR in control cells;
4 whereby a diagnostic value that is above the normal range is diagnostic of cancer.

1 49. The method of claim 48, wherein the cancer is bladder, colon,
2 breast, and prostate.

1 50. A method for providing a prognosis for a cancer patient,
2 comprising the steps of:

3 (a) determining the amount of the RNA component of human telomerase (hTR)
4 per cancer cell in a patient sample comprising cancer cells by:

5 (i) contacting the sample with a polynucleotide that specifically hybridizes
6 to a nucleotide sequence within an accessible region of hTR but that does not specifically
7 hybridize to a template region of hTR,

8 (ii) determining the amount of polynucleotide that has specifically
9 hybridized to hTR, and

10 (iii) correlating the amount of polynucleotide with an amount of hTR per
11 cancer cell in the sample; and

12 (b) comparing the amount of hTR per cancer cell with a prognostic value of hTR
13 per cancer cell consistent with a prognosis for the cancer;

14 whereby an amount of hTR per cell in the sample that is at the prognostic
15 value provides the particular prognosis.

1 51. The method of claim 50, wherein the cancer is neuroblastoma,
2 bladder, colon, breast, and prostate.

1 52. A method of determining the amount of the RNA component of
2 human telomerase (hTR) in a sample, comprising the steps of:

3 (a) amplifying from the sample a sequence of hTR to produce amplified hTR,

4 (b) amplifying from the sample a control polynucleotide to produce amplified
5 control polynucleotide,

1 (c) determining an amount of amplified hTR and an amount of amplified control
2 polynucleotide in the sample, and

3 (d) normalizing the amount of amplified hTR with respect to the amount of
4 amplified control polynucleotide to provide a normalized amount of hTR;

5 whereby the normalized amount of hTR provides a determination of the amount
6 of hTR in the sample.

1 53. The method of claim 52, wherein the control polynucleotide is
2 rRNA.

1 54. The method of claim 53, wherein the rRNA is 28S rRNA.

1 55. The method of claim 52, wherein the step of amplifying a sequence
2 of hTR comprises amplifying a sequence from an accessible region of hTR, wherein the
3 region comprises nucleotide positions 137-196, 290-319, and 350-380 of hTR.

1 56. The method of claim 52, wherein the efficiency of amplification of
2 the control polynucleotide is different than the efficiency of amplification of hTR.

1 57. The method of claim 52, wherein the efficiency of amplification of
2 the control polynucleotide is less than the efficiency of the amplification of hTR.

1 58. The method of claim 52, wherein said control polynucleotide is an
2 RNA, further comprising the step, before amplifying, of initiating reverse transcription
3 of hTR from a primer that hybridizes to hTR and initiating reverse transcription of the
4 control polynucleotide from a primer that hybridizes to the control polynucleotide, under
5 conditions such that initiating reverse transcription of the control polynucleotide is less
6 efficient than initiating reverse transcription of hTR.

1 59. The method of claim 52, wherein the step of amplifying a sequence
2 of hTR comprises:

3 (a) initiating chain elongation of an hTR complementary sequence from a primer
4 that hybridizes to a polynucleotide having the hTR sequence, and

1 (b) initiating chain elongation of the hTR sequence from a primer that hybridizes
2 to a polynucleotide having the hTR complementary sequence;
3 and the step of amplifying a sequence from the control polynucleotide comprises:

4 (a) initiating chain elongation of a control polynucleotide complementary sequence
5 from a primer that hybridizes to a polynucleotide having the control polynucleotide
6 sequence, and

7 (b) initiating chain elongation of the control sequence from a primer that
8 hybridizes to a polynucleotide having the control polynucleotide sequence;

9 wherein the conditions are selected such that the combined efficiency of initiating
10 chain elongation of the control polynucleotide sequence and complementary sequence is
11 less than the combined efficiency of initiating chain elongation of the hTR sequence and
12 complementary sequence.

1 60. The method of claim 52, wherein a difference in the combined
2 efficiency of initiating chain elongation of the hTR sequence and complementary
3 sequence, and the combined efficiency of initiating chain elongation of the control
4 polynucleotide and complementary sequence, is similar to a difference in the amount of
5 hTR and the control polynucleotide.

1 61. The method of claim 52, wherein the combined efficiency of
2 hybridization of the primers that hybridize to the control polynucleotide sequence and
3 complementary sequence is less than the combined efficiency of hybridization of the
4 primers that hybridize to the hTR sequence and the hTR complementary sequence.

1 62. The method of claim 52, wherein the combined length of the
2 primers that hybridize to the control polynucleotide sequence and the complementary
3 sequence is shorter than the combined length of the primers that hybridize to the hTR
4 sequence and the hTR complementary sequence.

1 63. The method of claim 52, wherein at least one primer that
2 hybridizes to the control polynucleotide sequence and the control polynucleotide
3 complementary sequence comprises mismatches with the control polynucleotide sequence
4 and the control polynucleotide complementary sequence.

1 64. The method of claim 52, wherein the control polynucleotide is
2 amplified with a first primer and a second primer having a sequence selected from the
3 group consisting of:

4 GCT AAA TAC CGG CAC GAG ACC GAT AG (SEQ ID NO:15)

5 GCT AAA TAC CGG CAC GAG AC (SEQ ID NO:16)

6 GCT AAA TAC CGG CAC GAG (SEQ ID NO:17)

7 GAT CTA AAT ACC GGC ACG (SEQ ID NO:18)

8 GAG CTA AAT ACC GGC ACG (SEQ ID NO:19)

9 GGT TTC ACG CCC TCT TGA ACT CTC TC (SEQ ID NO:20)

10 GTT TCA CGC CCT CTT GAA CTC (SEQ ID NO:21)

11 GTT TCA CGC CCT CTT GAA C (SEQ ID NO:22)

12 CTA GTT TCA CGC CCT CTT G (SEQ ID NO:23)

13 CTG GTT TCA CGC CCT CTT G (SEQ ID NO:24)

1 65. The method of claim 52, wherein the hTR sequence is amplified
2 with a first primer and a second primer having a sequence selected from the group
3 consisting of:

4 GAA GGG CGT AGG CGC CGT GCT TTT GC (SEQ ID NO:25)

5 GTT TGC TCT AGA ATG AAC GGT GGA AGG (SEQ ID NO:26)




FIG. 1.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/23619

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 91.1, 91.31, 172.3, 320.1, 325, 366; 536/23.1, 23.2, 24.31, 24.5; 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DIALOG, WPID, APS, BIOSIS, MASPAR
telomerase, antisense, RNA component, hTR, inhibit? activity,

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,583,016 A (VILLEPONTEAU et al) 10 December 1996 (10.12.96), in particular, col. 2, line 15 to col. 4, line 28, d col.s 7-11 (hTR sequence) and col. 12 lines 23-60 (oligonucleotide modification).	1-65
Y	WO 96/40868 A1 (COL SPRING HARBOR LABORATORY) 19 December 1996 (19.12.96), particularly Example 4, page 30 and generally.	1-65
X	WO 96/01835 A1 (GERON CORPORATION) 25 January 1996 (25.01.96), particularly pp. 3-14 and 24-28.	1-65
Y	FENG, J. et al. The RNA Component of Human Telomerase, Science. 01 September 1995. Vol. 269. pages 1236-1241, especially Fig. 2.	1-65

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

16 FEBRUARY 1998

Date of mailing of the international search report

25 MAR 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

USPTO, MARK L. SHIELLYA

Telephone No. (703) 308-9355

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/23619

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C12Q 1/68; C12P 19/34; C12N 15/00, 15/85, 15/86, 15/11; C07H 21/04; A61K 48/00

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

435/6, 91.1, 91.31, 172.3, 320.1, 325, 366; 536/23.1, 23.2, 24.31, 24.5; 514/44